

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Wyatt Paul, et al.
U.S. Serial No. : Not Yet Known (Continuation Application
of PCT/GB98/00542, filed 20 February
1998)
Filed : Herewith
For : PROTEIN COMPLEMENTATION IN TRANSGENIC
PLANTS
1185 Avenue Of The Americas
New York, New York 10036
August 20, 1999

Assistant Commissioner for Patents
Washington, D.C. 20231
Box: Patent Application

Sir:

PRELIMINARY AMENDMENT TO THE ACCOMPANYING CONTINUATION
APPLICATION FILED UNDER 37 C.F.R. §1.53

Applicants request that the following amendment be made in the
above-identified application:

In the Specification:

On page 1, after the title and before line 3, please insert the
following new sentence:

--This application is a continuation of PCT International
Application No. PCT/GB98/00542, filed 20 February 1998,
designating the United States of America, which is a
claiming priority of British Patent Application No.
9703681.8, filed February 21, 1997, the contents of which
are hereby incorporated by reference into the present
application.--

Wyatt Paul, et al.
U.S. Serial No.: Not Yet Known
(Continuation of PCT/GB98/00542,
filed 20 February 1998)
Filed: Herewith
Page 2

In the Claims:

Please amend the claims as follows:

In claim 3, delete "or claim 2";
In claim 4, delete "any one of claims 1 to 3" and insert
--claim 1--;
In claim 5, delete "any one of claims 2 to 4" and insert
--claim 2--;
In claim 6, delete "any one of claims 1 to 5" and insert
--claim 1--;
In claim 8, delete "any one of claims 1 to 5" and insert
--claim 1--;
In claim 9, delete "any one of preceding claims" and insert
--claim 1--;
In claim 10, delete "any one of claims 3 to 9" and insert
--claim 3--;
In claim 11, delete "any one of claims 5 to 10" and insert
--claim 5--;
In claim 12, delete "any one of claims 1 to 11" and insert
--claim 1--;
In claim 13, delete "any one of claims 1 to 12" and insert
--claim 1--;
In claim 14, delete "any one of preceding claims" and insert
--claim 1--;
In claim 17, delete "in claim 16";
In claim 18, delete "any one of claims 15 to 17" and insert
--claim 15--;
In claim 19, delete "any one of claims 15 to 18" and insert
--claim 15--;
In claim 20, delete "any one of claims 15 to 19" and insert
--claim 15--;
In claim 22, delete "any one of claims 15 to 19" and insert
--claim 15--;

Wyatt Paul, et al.
U.S. Serial No.: Not Yet Known
(Continuation of PCT/GB98/00542,
filed 20 February 1998)
Filed: Herewith
Page 3

In claim 23, delete "any one of claims 15 to 22" and insert
--claim 15--;

In claim 24, delete "any one of claims 15 to 23" and insert
--claim 15--;

In claim 25, delete "any one of claims 15 to 24" and insert
--claim 15--;

In claim 26, delete "any one of claims 15 to 25" and insert
--claim 15--;

In claim 27, delete "any one of claims 15 to 26" and insert
--claim 15--;

In claim 28, delete "any one of claims 15 to 27" and insert
--claim 15--;

In claim 29, delete "any one of claims 1 to 14 or by a
method as claimed in any one of claims 15 to 28" and insert
--claim 1--;

REMARKS

This application is a continuation of PCT International Application No. PCT/GB98/00542, filed 20 February 1998, designating the United States of America and claiming priority of British Patent Application No. 9703681.8, filed February 21, 1997.

By this Preliminary Amendment, applicants have hereinabove amended the specification on page 1 to insert the continuation data. Applicants have also amended claims 3-6, 8-14, 17-20, and 22-29. Applicants maintain that the amendments made hereinabove do not raise any issue of new matter. Accordingly, applicants respectfully request entry of the Amendment.

Wyatt Paul, et al.
U.S. Serial No.: Not Yet Known
(Continuation of PCT/GB98/00542,
filed 20 February 1998)
Filed: Herewith
Page 4

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone at the number provided below.

No fee other than the filing fee of \$940.00 is deemed necessary in connection with this Preliminary Amendment. However, if any other fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Reg. No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Ave of the Americas
New York, New York 10036
(212) 278-0400

08/20/99

JC644 U.S. PTO

Locket No. 1012/60030/JPW/AM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents
Washington, D.C. 20231

August 20, 1999

JC653 U.S. PTO

09/377502

08/20/99

S I R:

Transmitted herewith for filing are the specification and claims of the patent application of:

Wyatt Paul, Pascual Perez, Eric Huttner, and Andreas Stefan Betzner for
Inventor(s)

PROTEIN COMPLEMENTATION IN TRANSGENIC PLANTS

Title of Invention

Also enclosed are:

☒ 12 sheet(s) of ☐ informal ☒ formal drawings.☒ Oath or declaration of Applicant(s). (unsigned)☒ A power of attorney (unsigned)☐ An assignment of the invention to _____☒ A Preliminary Amendment☐ A verified statement to establish small entity status under 37 C.F.R. §1.9 and §1.27.

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED		NUMBER EXTRA*		RATE		FEE	
					SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	30-20	=	10	X	\$9.00	\$18.00	= \$	\$180.00
Independent Claims	3-3	=	0	X	\$39.00	\$78.00	= \$	\$ 0
Multiple Dependent Claims Presented: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No					\$130.00	\$260.00	= \$	\$ 0
*If the different in Col. 1 is less than zero, enter "0" in Col. 2					BASIC FEE		\$380.00	\$760.00
					TOTAL FEE		\$	\$940.00

☒ A check in the amount of \$ 940.00 to cover the filing fee.

☐ Please charge Deposit Account No. _____ in the amount of \$ _____.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any over-payment to Account No. 03-3125:

☒ Filing fees under 37 C.F.R. \$1.16.

☒ Patent application processing fees under 37 C.F.R. \$1.17.


☐ The issue fee set in 37 C.F.R. \$1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. \$1.311(b).

☒ Three copies of this sheet are enclosed.

☐ A certified copy of previously filed foreign application No. _____ filed in _____ on _____.
Applicant(s) hereby claim priority based upon this aforementioned foreign application under 35 U.S.C. \$119.

☒ Other (identify) Express Mail Certificate of Mailing bearing Express Mail
Label No. EM165674287US dated August 20, 1999.
Sequence Listing, and Information Disclosure Statement.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

**Application
for
United States Letters Patent**

To all whom it may concern:

*Be it known that, we,
Wyatt Paul, Pascual Perez, Eric Huttner, and Andreas Stefan Betzner
have invented certain new and useful improvements in*

PROTEIN COMPLEMENTATION IN TRANSGENIC PLANTS

of which the following is a full, clear and exact description.

PROTEIN COMPLEMENTATION IN TRANSGENIC PLANTS

This invention relates to pairs of parent plants for producing hybrid seeds and to methods for producing plants with a desired phenotype. The desired phenotype is an active enzyme, a regulatory protein or a protein which affects the functionality and/or viability and/or structural integrity of a cell. Preferably, the desired phenotype is substantially absent from the parent plants/lines. In particular, the invention relates to parent plants and methods involving plant lines for producing male-sterile plants and seeds.

The present invention describes a protein complementation system, with a variety of different applications. The system can be explained and exemplified with reference to obtaining male-sterile plants and embryoless seeds although it is not limited to these applications.

The use of dominant Artificial Male Sterility (AMS) in plants is described in WO95/20668. This document describes a binary system using two genes which together (but not in isolation) cause male sterility. The genes are brought together by crossing plants, each parent being homozygous for the gene, which generates a homogenous population of male sterile plants. WO95/20668 describes several ways to implement the gene binary system, including the following:

- i. a system based on activation of transcription: a transcriptionally inactive AMS gene is activated upon crossing by provision of the relevant transcription factor;

ii. a system based on activation of splicing: an AMS gene inactivated by the presence of an intron is activated upon crossing by provision of the relevant maturase;

iii. a system based on the suppression of a stop codon during translation: an AMS gene inactivated by introducing an artificial stop codon in the ORF, is activated upon crossing by provision of an artificial stop suppressor tRNA for the introduced stop codon.

iv. a system based on sequence-specific gene inactivation: One parent contains a modified male fertility gene and a transgene which inactivates only the unmodified male fertility gene. The other parent contains a transgene which inactivates only the modified male fertility gene. In the hybrid both the modified and unmodified male fertility genes are inactivated causing male sterility.

v. a system based on preventing restoration of male fertility by a restorer gene: the first parent contains the AMS gene and the restorer gene, and the second parent contains a gene inhibiting the action of the restorer gene.

However, the binary systems described above have so far proved complex to implement and have encountered a variety of difficulties.

For example, it has been found that the use of a suppressor tRNA (described in Betzner et al. 1996,

- Abstract of the 14th International Congress of Plant
Reproduction, Lorne, Australia) can have deleterious
consequences for some plant species. While this does
not preclude its use, it does make the screening of
5 suitable transgenic plants more labour intensive than
desirable. Another example is the leakiness of the T7
promoter (described in EP-A-0589841). Some plants
transformed with a T7 promoter driving Barnase were
sterile in the absence of the T7 RNA polymerase. Again,
10 this does not preclude use of the system but it does
make it difficult to identify suitable transgenic
plants. Furthermore, in certain plants the gene binary
system is sub-optimal since not all of the required
genetic elements are fully characterised.
- 15 Two areas of prior art have been explored which have
resulted in a phenotype conferred to a plant by the
combination of two proteins.
- 20 In 1989, Hiatt and coworkers (Nature, vol. 342, p. 76-
78) described the production of a functional antibody in
tobacco by crossing tobacco plants expressing a gamma
immunoglobulin gene and a kappa immunoglobulin gene.
- 25 Problems were, however, encountered with this system.
Since the light and heavy chains of an antibody interact
through disulfide bridges, the bridges were unable to
form in the reducing environment present in the
cytoplasm. Assembly of a functional antibody in plants
30 thus requires that both chains are targeted to the
endoplasmic reticulum then secreted to the apoplast (the
space between cells). The production of antibodies in
plants has thus been limited to the production of
secreted antibodies or the production of single chain

antibodies.

In 1992 Lloyd et al. (Science, vol. 258, p. 1773-1775) described the transfer in Arabidopsis and tobacco of two
5 maize genes coding for the transcription factors R and C1. Ectopic expression of these genes separately in heterologous plants has some effect on the transcription of endogenous genes. In particular the genes have some effect in isolation, and this may preclude their use for
10 applied purposes. Co-expression of the two genes had more dramatic qualitative and quantitative effects, than expression of either gene alone. However, these genes have properties severely limiting their usefulness and their general inapplication is described in the paper.

15 It has been shown that the Arabidopsis transcription factors Apetala3 and Pistillata can be ectopically co-expressed, and jointly in concert cause a new phenotype in the Arabidopsis flower (Krizek and Meyerowitz, 1996, Development, vol. 122, p. 11-22). The limitations
20 described above for the R/C1 proteins also apply in this case.

The present invention describes a protein
25 complementation system which overcomes many of the problems and difficulties associated with known gene binary systems. The protein complementation system according to this invention is based on the expression of two or more gene sequences in a single plant, which
30 polypeptides/proteins, associate, interact or come together to form an active enzyme, a regulatory protein or a protein which affects the functionality and/or viability and/or the structural integrity of a cell. Hereinafter, in this text all references to a protein

which affects the structural integrity of a cell also describes a protein which may, in addition, or alternatively, affect the functionality and/or viability of a cell. Some polypeptides/proteins may fall in more than one of these categories. None of the individual gene sequences present in a given plant lead to a significant phenotypic effect in these plants.

The present invention describes the creation of a plant which has a desired phenotype through expression of an active enzyme, regulatory protein or protein which affects the structural integrity of a cell (eg. a membrane destabilizing protein). The plant may be obtained by crossing a pair of parent plants a and b.

Plant a contains one or more gene sequences which encode a polypeptide(s) or protein(s) (A) with little or no activity so that the desired phenotype is not significantly (or substantially) caused by expression of the one or more genes in plant a alone. Plant b also contains one or more gene sequences which encode a polypeptide(s) or protein(s) (B) also, with little or no activity so that the desired phenotype is not significantly (or substantially) caused by expression of the one or more genes in plant b alone. When plants a and b are crossed, the resulting hybrid expresses both polypeptides and/or proteins A and B. These two polypeptides/proteins associate, interact or come together to form an active enzyme, regulatory protein or protein which affects the structural integrity of the cell, with the result that the daughter plant displays the desired phenotype. NB: From hereon, when discussing the polypeptides/proteins A or B they will be referred to only as 'polypeptides' for the sake of convenience.

This protein complementation binary system is simpler than the previously described binary systems since there is no need for interaction between genes, no required modification of the expression of genes and no
5 modification of the level of expressed polypeptides in the daughter plant compared to the parent plants.

The present invention is described with reference to the Figures which are:

10

FIGURE 1A; Barnase coding sequence;

FIGURE 1B; Intergenic sequence;

FIGURE 1C; Barstar coding sequence;

15 FIGURE 1D; Translational fusion of ORF Peptide A**/(Gly4 ser)3 Linker peptide / GUS;

FIGURE 1E; Nucleotide sequence of Translational fusion of Ubiquitin genomic sequence and ORF Peptide A***;

FIGURE 1F; Nucleotide sequence of Translational fusion of Ubiquitin genomic sequence and ORF peptide B***

20 FIGURE 1G; DNA sequence of IPCR (inverse polymerase chain reaction) primers (example 1)

FIGURE 2; Schematic illustration of pepA*

and pepB* construction by Inverse PCR (IPCR)

25 FIGURE 3A; In vitro construction from synthetic oligonucleotides of S-peptide, S(+5)-protein and S-protein;

FIGURE 3B; In vitro construction from synthetic oligonucleotides of the sequence encoding the S-peptide and the (Gly4-Ser)3 linker;

30 FIGURE 4A; protein and DNA sequences of S-peptide and S-peptide with (Gly4-Ser)3 linker;

FIGURE 4B; protein and DNA sequences of S(+5)-protein and S-protein.

FIGURE 4C(i); PCR amplification product encoding partial

AOX3 targeting signal;

(ii); ORF encoding AOX3 targeting sequence
(underlined) and S-peptide

(iii); ORF encoding AOX3 targeting sequence
5 (underlined) and S-peptide/(Gly4 Ser)3/GUS

(iv); ORF encoding AOX3 targeting sequence
(underlined) and S-protein

(v); translational fusion of Ubiquitin genomic
sequence and ORF of S-protein;

10 FIGURE 4D; nucleotide sequence of IPCR primers (example
3)

FIGURE 5; production scheme for embryoless maize grains.

15 Embryoless seeds harvested from female rows only = 100%
of embryoless maize seeds

or

20 Seeds harvested from all the field plants =
approximately 80% of embryoless maize seeds:

note that if this sort of seeds harvesting is suited a
random sowing with 10% of male plants and 90% of female
plants is desirable and possible.

25

Legend

male parent A
expressing pepA* in embryos
30 Genotype: emb-pepA*/emb-pepA*
or
emb-pepA* linked to Herbicide
resistance/emb-pepA* linked to
herbicide resistance

female parent B
expressing pepB* in embryos only
Genotype: emb-pep*/emb-pepB* in a
5 male sterile cytoplasmic environment
or
emb-pepB*/emb-pepB*
Artificial Male Sterility linked to
Herbicide Resistance/+

10

According to a first aspect of the invention there is provided a pair of parent plants for producing seeds comprising:

15

- (i) a first parent plant containing one or more gene sequences encoding a polypeptide A; and
- (ii) a second parent plant containing one or more gene sequences encoding a polypeptide B;

20

wherein the polypeptides A, B, when expressed separately in different plants, do not form an active enzyme a regulatory protein or other protein which affects the structural integrity of the cell but when expressed in the same plant do form an active enzyme, regulatory
25 protein or other protein which affects the structural integrity of the cell. Presence of the active enzyme, regulatory protein or protein which affects the structural integrity of the cell in a single plant, is the desired phenotype.

30

The present invention includes the scenario of inter-

extra-genic repression/complementation/suppression; that is, where a mutation in one subunit of a multi-subunit complex can complement a mutation in another sub-unit in order to restore the active enzyme, regulatory protein or protein affecting the structural integrity of the cell. In such a scenario, the polypeptide(s)/protein(s) A and B may be the same in the two parent plants, with the exception of the different mutations. Examples include the *E.coli* regulatory proteins as described by Tokishita S.I., and Mizuno T., 1994, *Mol. Microbiol. (UK)*, 13/3, 435-444 and the GroES and GroEL proteins of *E.coli* as described by Zeilstra-Ryalls J., et al., 1994, *J. Bacteriol. (US)*, 176, (21), 6558-65.

15 In the present invention, the pair of parent plants can be described as a pair of complementary plants for producing hybrid seeds or even a pair of complementary transgenic plants for producing transgenic hybrid seeds.

20 It is most likely that at least one of the pair of parent plants is transgenic. When used herein the term 'transgenic' refers not only to genetic material from another species but to genetically manipulated DNA from the same plant or species. The genetic manipulation of the plant may be by a microbiological process such as *Agrobacterium tumefaciens* (Horsch R.B., Fry J.E., Hoffman N.L., Eichholtz D., Rogers S.G., Fraley R.T., (1985), *Science*, 227 : 1229-1231)). Alternative manipulations include biolistic transformation, a technique also well known in the art, the use of *Agrobacterium rhizogenes*, particle gun, electroporation polyethylene glycol or silica fibers.

The present invention may be applied to any plant, in

particular, maize, wheat, tomato, oilseed rape, barley, sunflower, linseed, peas, beans, melon, pepper, squash, cucumber and egg plant (aubergine) and other broad acre plants.

5

Use of the term "one or more gene sequences encoding a polypeptide...." refers to any number of stretches of genetic material (preferably DNA) which can encode one or more peptides/polypeptides/proteins. Thus

10 "polypeptides" A or B can actually comprise more than one amino acid sequence which may or may not be linked or associated. There is no restriction on the location in the parent plant genome of the one or more gene sequences. Where more than one gene sequence is
15 present, encoding for more than one peptide/polypeptide/protein, the relationship between the encoded sequences in each parent plant is only relevant to the extent that the parent plant does not display the desired phenotype (to any significant
20 level). When the one or more gene sequences encoding a polypeptide A are expressed in the same plant as the one or more gene sequences encoding polypeptide B, then the result, according to the invention is the phenotype of an active enzyme, a regulatory protein or a protein
25 which affects the structural integrity of a cell. Proteins which affect the structural integrity of a cell include proteins that destabilise or create holes or ion channels in cellular membranes.

30 A particular application of the present invention is the production of male-sterile plants. Accordingly, the polypeptides A, B when expressed in the same plant may cause male-sterility by ablation of the tapetum. An alternative application, also of the first aspect of the

invention is the expression of polypeptides A, B in the same plant which form an active enzyme, a regulatory protein or protein which affects the structural integrity of a cell, which, through cell ablation in a specific tissue results in a different phenotype, as described below.

In addition to causing male-sterility, potent hydrolases like Barnase can be used for other applications where cell ablation is needed, for example to remove an unneeded organ from a hybrid crop. This may contribute to reducing downstream processing costs. One example is the production of embryoless seeds, which is now described as follows: In the production of flour (from wheat) or semolinas (from maize or wheat) or corn flakes (from maize) or for other uses, it would be desirable to have seeds with no embryo. The use of embryo specific promoters in the first aspect of the invention above would enable ablation of embryos in seeds, in a cross dependent manner. That is, in the seeds produced by the plant containing one or more gene sequences encoding polypeptide A, pollinated with pollen from a plant containing one or more gene sequences encoding polypeptide B. Self pollination of plant a has to be prevented, for example by making plant a male-sterile. A possible production scheme for valuable embryoless maize grains would be the following: generate a plant containing one or more gene sequences encoding polypeptide A (plant a) and a plant containing one or more gene sequences encoding polypeptide B (plant b), designed so that combination of polypeptide A and polypeptide B in one seed results in embryo ablation. Figure 5 shows a production scheme for embryoless maize grains according to the invention.

The biochemical composition of plants can also be manipulated according to the first aspect of the invention, for example by fatty acid biosynthetic enzymes. Where the presence of an unusual but valuable fatty acid in the plant has a deleterious effect on the plant, it would be useful to be able to produce seeds with the unusual (fatty acid) oil through a cross between two lines having a normal (or quasi normal) oil composition (to the extent that each parent line is not deleteriously effected). Splitting the enzyme responsible for the valuable fatty acid biosynthesis in two or more inactive parts, provides a practical way of producing the seeds with the valuable oil. Where the enzyme responsible for the desired trait is heteromultimeric, separating the genes from the various monomers in the two parent plants is a simple way to implement the invention. More generally, this invention can be used to obtain hybrid seeds or hybrid plants with a particular phenotype which neither parent has. In particular, this invention can be used to create hybrid plants, resistant to a herbicide, via the crossing of two parent plants: Each of the parent plants expresses one or more non-functional parts of an active enzyme, regulatory protein or protein which effects the structural integrity of a cell, which is directly or indirectly responsible for herbicide resistance. As the one or more genes in each parent plant responsible for the trait will segregate independently, this will result in the gametes of such hybrid plants (especially pollen grains) giving rise to a lower transfer of the herbicide resistance trait to relatives or to weeds (in comparison with a classical single gene). If the hybrid seed is the harvested desirable product, expression of the

desired trait would be restricted to the seed endosperm and embryo since these tissues are genetically hybrids.

The active enzyme, regulatory protein or protein which
5 affects the structural integrity of a cell is preferably
localised to a tissue specific (ie. present only in a
selected tissue). This requires that one or both of the
gene sequences encoding the polypeptides A, B are
operatively linked to an appropriately stimulated
10 promoter, eg. a tissue specific promoter so as to
produce the desired phenotype. Where only one of the
polypeptides is limited to expression in a selected
tissue, the other polypeptide requires constitutive
expression or at least an expression pattern which
15 overlaps with that of the first polypeptide.

As described above, the expression may be seed or embryo
specific and promoters for such tissue specificity are
well known in the art. In the case of male-sterility,
20 the promoter is preferably tapetum specific. Such
promoters known in the art include the TA29 promoter
(EP-A-0344029), the A9 promoter (Paul et al 1992, Plant
Molecular Biology, vol. 19, p. 611-622) and the
promoters described in WO95/29247. In order for
25 heterozygous plants to have the desired phenotype,
promoters must be active at the sporophytic level.

The choice of gene sequence for producing an active
enzyme, regulatory protein or protein which affects the
30 structural integrity of a cell depends, of course, on
the desired phenotype. Any gene sequence encoding an
active enzyme, regulatory protein or protein which
affects the structural integrity of a cell can be used
provided that the protein activity can result from the

association, interaction or combination of two or more polypeptides encoded by two or more gene sequences and that their activity can result in the desired phenotype.

Immediately obvious proteins which can be suitable are those which are naturally encoded by two or more polypeptides and which self-assemble to form the final protein structure. The individual polypeptide units (subunits) should have no significant activity *in vivo*.

Suitable proteins for use according to the invention include natural heterodimeric proteins such as the C1-R maize proteins and the Apetala3-Pistillata (Ap3-Pi) *Arabidopsis thaliana* proteins. When present in the tapetum, the dimer protein Ap3-Pi can activate genes responsive to this transcription factor (which would normally be inactive because this transcription factor is normally absent from, or present at a low level in, the tapetum). The activated gene is preferably, but not necessarily, endogenous to the plant of interest. For example, expressing the dimer Ap3-Pi in the tapetum of maize will activate transcription of genes normally involved in flower development in other floral organs, and will prevent normal pollen maturation. The level of sterility of such a system can be improved by also engineering into the daughter plant a gene sequence which is affected by the produced active enzyme or regulatory protein.

One example is the introduction into one of the parent lines of a gene sequence from Barnase or PR-Glucanase under the control of the Apetala3 promoter (pApetala3). The Apetala3 promoter is responsive to the Ap3-Pi dimer and thus expression of the Barnase or PR-Glucanase protein occurs in the daughter plant. Such a system

provides for the enhancement of plant male-sterility with the additional advantage of being under a strict control mechanism (via the pApetala3). Thus, the cause of the desired phenotype may be direct, ie. a direct result of the active enzyme, regulation protein or protein which affects the structural integrity of a cell, or may be indirect, ie. acting via an intermediate factor. Other transcription factors, for use in the invention, exist already as, or can be engineered to, a heterodimeric form, for example using the dimerisation domains described below. These include artificial transcription factors made by the association of a DNA binding domain and an activation domain of different origins.

An alternative use of the Apetala3-Pistillata system, is the complementation of mutations in sub-units of the proteins. For example, one parent plant may express both proteins but with a mutation in one or the other so that the plant does not have the active dimer. The other parent plant may also express both proteins, in this case, a mutation being in the other protein. The second parent plant would not express the active dimer. A cross between the two parent plants would result in expression of genes to produce an active dimer.

Ectopic expression of the subunits for these transcription factors can be used to modulate expression of their target gene and cause male sterility or other traits (including pleiotropic effects) in a cross-dependent manner.

It is also possible to use, according to the first aspect of the invention proteins which have to be

"artificially" split into two or more nucleic acid coding sequences. The resulting polypeptides/proteins must associate, assemble, interact or come together when expressed in the same plant to form an active enzyme, regulatory protein or protein which affects the structural integrity of a cell. Such artificial splitting of enzymes and proteins is today easily achieved by predicting where the protein can be split into two or more domains, for example predicting by structural biochemistry such as X-ray crystallography, functional protein analysis in mutants, structure prediction from sequence analysis or by limited proteolysis, amongst other techniques. In this way, the random coil or other suitable regions are identified as places where the protein may be split.

Examples of artificially split proteins include:

- Barnase: This protein has been widely used to cause cell ablation, when expressed in specific tissues. Under the control of a tapetum specific promoter, expression of a Barnase gene causes male-sterility in many plant species (EP-A-0344029). It is known that the Barnase protein can be split into two polypeptides, which *per se* have no catalytic activity [in vitro]. When put together the two polypeptides can self-assemble to produce an enzyme whose product has RNase activity. (Sancho and Fersht, 1992, J.Mol.Biol., 224, 741-747).
- RNase A can also be used. It was shown, as long ago as 1959 (Richards and Vithayathil, J.Biol.Chem., 234, 1459-1465) that RNase A can similarly be split by mild proteolytic treatment into two polypeptides which can then reassociate and produce an active enzyme.

In order to implement a system, according to the present invention, involving artificially split proteins, it may be necessary to design genetic constructs in order to express the polypeptides therefrom. In order to design the genetic constructs whose products will associate to form the active enzyme some modifications may be required. For example, a methionine codon can be added in front of the ORF encoding the second half of the active enzyme and a stop codon can be added after the ORF encoding the first half of the active enzyme. If the polypeptides are expressed as the C terminal part of a translational fusion to another protein or to a protein targeting sequence, then a start codon may be absent from the ORF of polypeptide A and/or polypeptide B, whereas a stop codon is still needed to terminate the ORF of polypeptide A and polypeptide B, respectively. If polypeptide A or B is expressed as the N-terminal part of a translational fusion to another protein, then the ORF of polypeptide A or B will start with a methionine codon whereas the termination codon is provided by the ORF of the other protein to which it is fused. Such genetic construct design is commonplace and well known to the person skilled in the art.

The invention may also be practised by expressing two portions of two different enzymes that together give a different activity than either of the intact parent proteins.

Preferably, both parent plants are homozygous with respect to the gene sequences encoding polypeptide A or polypeptide B. Such genotypes ensure that all offspring will express the active enzyme, regulatory protein or

protein which affects the structural integrity of the cell.

5 If one or more of the polypeptides (A or B) is/are small
and there are doubts that any of them will be stable in
a cell, it is possible to use well-known systems wherein
the small polypeptide is fused in frame to a "carrier
protein" which protects it from being degraded or
increases its proteolytic stability, but retains its
10 freedom to interact with the other polypeptide(s) to
form the active enzyme, regulatory protein or protein
which affects the structural integrity of a cell.

15 The carrier protein can be chosen so that the
polypeptides A or B are not affected by the fusion. One
suitable carrier protein is the β -Glucuronidase (GUS)
protein, which tolerates addition to its NH₂ end, and is
a good reporter gene in plants. In this case, one can
use the level of GUS activity to evaluate the expression
20 level of the fused small polypeptide. This can be
useful for screening primary transformants. Another
suitable carrier protein is ubiquitin (Hondred and
Vierstra, 1992, Curr. Opin. Biotechnol. 3, 147-151;
Vierstra, 1996, Plant Mol. Biol., 32, 275-302). When
25 fused in frame to the carboxy-terminus of ubiquitin,
proteins accumulate significantly in the plant
cytoplasm. In addition artificial ubiquitin protein
fusions resemble natural ubiquitin extension proteins,
e.g. UBQ1 of *Arabidopsis thaliana* (Callis et al., 1990,
30 J. Biol. Chem., 265, 12486-12493), in that they are
cleaved precisely at the C-terminus of ubiquitin (after
Gly 76 by specific endogenous proteases. This process
releases the "attached" protein or peptide moiety from

the fusion protein and thus permits polypeptide A and B to assemble into a functional enzyme or protein. Also, for the purpose of protecting small proteins from cytoplasmic proteolysis, translational products may be
5 enlarged by fusing them to protein targeting signals, e.g. the C-terminus (Whelan and Glaser, 1997, Plant Mol. Biol. 33, 771-781) and be directed to specific locations in the cell such as to mitochondria. A suitable signal, for example, is the one found in the AOX3 protein of
10 soybean (Finnegan and Day, Plant Physiol., 1997, 114, pp 155) which would add 50 amino acids to polypeptide A and B, respectively. Import associated proteolytic processing will remove the targeting signal by cleavage after Met50 thereby releasing the free polypeptides A and
15 B into the mitochondria where they combine to disrupt mitochondrial function and thus to compromise cell viability.

In some cases, when expressed in two or more portions,
20 the polypeptides may not spontaneously associate, assemble, interact or come together in vivo to reform an active protein, or regulatory enzyme or protein which affects the structural integrity of a cell. In other cases the association of the polypeptides may be weak so
25 that little active reconstituted protein is formed. To circumvent these problems, each protein portion may be linked to a protein dimerisation domain, thus enabling the portions to be brought together in vivo. Such protein dimerisation domains are found in many proteins
30 that naturally form dimers or multimers and the linking technique is well known in the art.

For example, the human cysteine-rich protein LIM double zinc finger motif has been fused to the Gal4 and VP16

proteins. In contrast to the unmodified Gal4 and Vp16 proteins the LIM-Gal4 and LIM-VP16 associate in vitro and in vivo (in NIH 3T3 mammalian cells) forming an active transcription factor (Feuerstein et al., 1994, Proc.Natl.Acad.Sci. U.S.A. 91, 10655-10659). The LIM motif is found in many organisms. For example, a sunflower pollen specific protein with a LIM domain has been identified (Batz et al., 1996, Plant Physiology (Supplement III, 59). Other protein dimerisation domains exist such as the leucine zipper (Turner, R. and Tijian R., 1989 Science, 243, 1689-1694), the helix-loop-helix (Murre et al., 1989, Cell, 56, 777-783), the ankyrin Blank et al., 1993, Trends in Biochemical Sciences, 17, 135-140) and the PAS (Huang et al., 1993, Nature, 364, 259-262) domains.

One may also wish to ensure that the genes encoding polypeptides A or B are inserted in the genomes of parents a and b at an identical position (or at tightly linked positions) so that their chance of co-segregation in the transgenic hybrid is low. This can be advantageous, for example in the production of hybrid seed since the two genes that are used to create the male-sterile parent plant will subsequently segregate. Thus, F1 hybrid progeny are 100% male fertile since no hybrid plant can inherit both components of the male-sterility system.

The gene sequences carried by the parent plants a and b which encode part of the active enzyme, regulatory protein or protein which affects the structural integrity of a cell may be from a different organism. The gene sequences do not have to be plant derived and include genes from microbial or other sources. For

example, the gene sequences may be Arabidopsis endogenous sequences in maize or tomato parent plants. Also, the gene sequences may be those which, in combination with a tissue specific promoter, are expressed in a tissue in which the gene sequences are not normally expressed.

According to a second aspect of the invention there is provided a method for producing a plant having a desired phenotype of an active enzyme, a regulatory protein or a protein which affects the structural integrity of a cell, the method comprising crossing a first plant line with a second plant line wherein the first line contains one or more gene sequences encoding a polypeptide A which is part of an active enzyme, regulatory protein or protein which affects the structural integrity of a cell but which line does not have the phenotype and wherein the second line contains one or more gene sequences encoding a polypeptide B which is complementary to the polypeptide or protein A but which line does not have the desired phenotype. Here, the term "complementary" means that when expressed in the same plant the polypeptides A and B associate, interact or come together to form the phenotype of an active enzyme, a regulatory protein or protein which affects the structural integrity of a cell.

Such a method may incorporate one or more of the features described above for the first aspect of the invention and the invention contemplates the application of these aspects according to the second aspect of the invention.

According to a third aspect of the invention there is

provided a seed or plant obtainable from a pair of plants according to the first aspect of the invention or by a method according to the second aspect of the invention.

5

According to a fourth aspect of the invention there is provided a seed or plant having a phenotype of an active enzyme, regulatory protein or protein which affects the structural integrity of the cell, which is caused by the
10 combined action of two or more transgenes, the transgenes not being present on the same copy of a chromosome. The preferred embodiments of the first, second and third aspects of the invention also apply to the fourth aspect. This means that the two or more
15 transgenes are either on different chromosomes, or on different copies of the same chromosome, ie. the plant is made by a cross.

The invention will now be described by the following
20 non-limiting Examples:

EXAMPLE 1

Splitting the Barnase Gene into Two Components (Figure
25 1)

The results of Sancho and Ferscht, 1992; J.Mol.Biol., 224, 741-747 show that Barnase activity can be obtained by combining a peptide A containing amino acids 1 to 36
30 of the mature Barnase protein and peptide B containing amino acids 37 to 110 of the mature Barnase protein. The allele of Barnase which is described in Sancho and Ferscht is a mutant which has a methionine at position 36, allowing cyanogen bromide to cleave between 36 and

37 and produce the 2 peptides. The following genetic constructs, to express the peptides, were prepared:

Peptide A:

i. A Barnase gene with a methionine codon (amino acid position -1) added before codon 1 of the mature Barnase sequence so that translation can take place as described in Paul et al, 1992, Plant Mol.Biol., 19, 611-622.

ii. An ORF coding for a peptide called A*, containing a methionine followed by amino acids 1 to 35 of mature Barnase protein followed by an Ochre stop codon.

iii. A gene made of ORF A* under control of the A9 promoter by using IPCR on our plasmid p3079, which contains the AMS gene pA9-Barnase (as in i. above) - Barstar - CaMV 3' region. (See Figure 2).

Plasmid p3079 was constructed by cloning a fragment containing the ORFs for Barnase-Barstar, obtained by PCR from pWP127-(Paul et al, 1992, *supra*), in our plasmid p1415, which is a derivative of pWP91 (WO-A-9211379)

where the EcoRV restriction site has been converted to HindIII. IPCR was then performed on p3079 using primers B3 and B4 (see Figures 1 and 2) designed so that the sequence between codon 36 of Barnase and stop codon of Barstar is not part of the amplified product. The IPCR amplified sequence was then circularised by ligation and the resulting plasmid was introduced into *E. coli*. The plasmid was then prepared, cut with EcoRI and the fragment containing the ORF A* was cloned in the EcoRI sites of p1415, so that ORF A* would be under the

control of the A9 promoter from a sequence not treated by PCR. The resulting plasmid p2022 contains ORF A* in the A9 expression cassette.

- 5 iv. An ORF coding for a peptide called A**, comprised of a start methionine codon followed by amino acids 1 to 36 of the mutant Barnase (Sancho and Ferscht, 1992, supra) but lacking a stop codon.
- 10 This was obtained by PCR on template p2022 with primers B5 (retaining the XbaI site at the 5' end) and B6 generating a blunt 3' end.
- 15 v. A gene made of the translational fusion of ORF A** and the ORF of (Gly4 Ser) β /GUS under the control of the A9 promoter, the product of which shows peptide A fused in frame to the N-terminus of (Gly4 Ser) β /GUS (Figure 1D).
- 20 This was obtained by replacing the S-peptide ORF in plasmid p2028 (see example 3) with the ORF of plasmid A** (iv). For ORF replacement an IPCR was performed on plasmid p2028 using primers B7 (retaining the Xba site at the 5' end) and B8 (generating a blunt 3' end) to
- 25 delete the region encoding the S-peptide from the S-peptide-GUS translational fusion. After digest with XbaI, the PCR fragment encoding peptide A** (iv) was inserted XbaI/blunt into the acceptor DNA generated by IPCR.
- 30
- vi. An ORF coding for peptide A***, essentially identical to peptide A**(iv) but lacking a methionine start codon and containing an amber stop codon.

This was obtained by PCR on template p2022 using primers B9 (producing a blunt 5' end) and B10 (introducing a BamHI site at the 3' end). The 3' end of the PCR product was digested with BamHI for construction of the ubiquitin-peptide A*** translational fusion (below).

vii. A gene made of the translational fusion of genomic DNA encoding ubiquitin and the ORF A*** under the control of the A9 promoter, the product of which shows peptide A*** fused in frame to the C terminus of ubiquitin (Figure 1E).

The genomic DNA encoding ubiquitin was obtained by PCR from chromosomal DNA of *Arabidopsis thaliana*. The PCR primers Ubq16F and Ubq1R were designed to amplify the ubiquitin encoding sequence from the extension protein gene UBQ1, first described by Callis et al. (1990, supra). Restriction sites for XbaI (at 5' end) and BamHI (at 3' end), introduced during thermocycling, were used to clone the PCR fragment under the control of the A9 promoter of p1415 digested with XbaI and BamHI to yield plasmid p3245. IPCR was then performed on p3245 using primers UBQ1a and UBQ1b to generate a blunt acceptor end immediately after the ubiquitin codon Gly 76 and at the 3' end to reconstitute the BamHI restriction site for cloning. After BamHI digest this construct served as acceptor for the PCR fragment encoding peptide A*** (vi).

30 Peptide B:

i. An ORF coding for a peptide called B* which starts with a methionine codon followed by codons 37 to 110 of the mature Barnase sequence. In effect this transfers the methionine 36 of the mutant Barnase gene (Sancho and

Ferscht, 1992, *supra*) from peptide A to peptide B, yielding peptides A* and B*.

- ii. Gene for ORF B* containing the ATG (amino acid position -1) of Barnase (in p3079) fused to codon 37 of Barnase, under control of the A9 promoter, by deleting (by IPCR with suitable primers) (see below) codons 1 to 36 of the mature Barnase sequence.
- 10 This was done by performing on p3079 an IPCR reaction using primers B1 and B2, (Figures 1 and 2) designed so that the sequence between codon 2 and codon 36 of Barnase is not part of the amplified product (see Figure 2). The IPCR product is treated as described above for
- 15 ORF A*, and cloned under control of the A9 promoter in p1415. The resulting plasmid p2023 contains ORF B* - Barstar in the A9 expression cassette.
- iii. An ORF encoding peptide B*** which differs from B* (i) in that it lacks the start methionine.
- 20
- iv. A gene made of the translational fusion of genomic DNA encoding ubiquitin and the ORF B*** under the control of the A9 promoter, the product of which shows
- 25 peptide B*** fused in frame to the C-terminus of ubiquitin (Figure 1F).
- IPCR as performed on plasmid p2023 (above) with primers B11 and B12, retaining the XbaI site at the 5' end of B* but removing the ATG start and leaving a blunt 3' end.
- 30 After digest with XbaI, the IPCR product served as an acceptor for the ubiquitin encoding DNA. The latter sequence was obtained by PCR from plasmid p3245 (above) with primers Ubq16F and Ubq1b retaining an XbaI site at

the 5' end while leaving the 3' end blunt. After digest with XbaI, the IPCR and the PCR product were ligated to yield the translational fusion shown.

- 5 In Figure 1G: The nucleotide sequences of primers are listed which were used for PCR and IPCR, respectively.

10 In Fig. 2: Circular plasmid p3079, containing the A9-driven barnase/barstar gene (Figure 1) in p1415, served as template for Inverse PCR. As the PCR primers (Figure 1) pointed into opposite directions, the IPCR yielded a linear double-stranded plasmid DNA from which the region in between the 5' ends of the annealed PCR primers was deleted (below). Intramolecular ligation would then
15 yield circular deletion plasmids which were introduced into *E.coli* for further subcloning.

Also In Fig. 2-:

lane 1:

- 20 A schematic (not to scale) representation is shown of plasmid p3079. The different structural parts of the coding regions are highlighted. ATG and TAA represent the start and stop codon of barnase and barstar, respectively. The relative positions of codons 35, 36
25 and 37 of the mature Barnase protein are indicated.

lane 2:

- 30 IPCR with primers B1 and B2 deleted codons 1 to 36 of the mature Barnase protein. Intramolecular ligation of the linear deletion plasmid then fused the ATG start codon to codon 37 yielding the pepB*/barstar region.

lane 3:

IPCR with primers B3 and B4 deleted the sequence

downstream of the barnase codon 35 as indicated. Intramolecular ligation of the linear deletion plasmid then fused the barnase codon 35 to the barstar stop codon yielding the pepA* sequence.

EXAMPLE 2

Plant Transformation with the Genetic Constructs in Example 1

5

Genes pA9-A* and pA9-B* expressing a polypeptide A and a polypeptide B from the A9 promoter (WO92/11379) were cloned into derivatives of the plant transformation vector pBin19 Beven et al., 1984, Nucl. Ac. Res. 12, 8711 Frish et al., 1995 Plant Mol. Biol., 27, 405-409 and Arabidopsis plants containing pA9-polypeptide A, or pA9-polypeptide B, or both genes, were obtained. Plants containing both genes were male sterile, whereas plants containing one gene were unaffected by the transgene.

10

15 Plants with one gene were allowed to self, their progeny was harvested, and was analysed to identify homozygous and heterozygous T1 plants. T1 plants with pA9-polypeptide A were crossed with T1 plants with pA9-polypeptide B. The hybrid seeds obtained displayed the predicted phenotype: wild type if containing one gene only, and male sterile when containing the two genes.

20

Genes are introduced into maize and into tomato by biolistic or Agrobacterium-mediated transformation, and plants are regenerated and assessed for male fertility in a similar way. (Mornish et al., 1990 Biol/Technology 8, 833-839 and Fillati et al., 1987 Bio/Technology 5, 726-7390).

25

30 EXAMPLE 3

Splitting an RNaseA gene into two components
(Figures 3 and 4)

From the work of Richards and Vithayathil (1959 *supra*), we know that the enzyme RNaseA can be cleaved (by the protease subtilisin) to generate two polypeptides: the S-peptide contains amino acids 1 to 20 of RNaseA, and the S-protein contains amino acids 21 to 124 of RNaseA.

When combined, the S-peptide and the S-protein associate, and reconstitute an active enzyme. The last 5 amino acids of the S-peptide are not needed for reconstituting RNaseA: a smaller S-peptide made of amino acids 1 to 15 is sufficient. Genes which express the S-peptide and the S-protein under control of the A9 promoter were used to develop a system according to the invention.

The starting material was a synthetic gene coding for bovine pancreatic RNaseA (Vasanth and Filpula, 1989, Gene 76 53-60). A gene coding for the ORF of RNaseA was made using synthetic oligonucleotides (see Figures 3A and 3B). The nucleotide sequence of the gene was designed to be compatible with maize codon usage, according to Fennoy and Bailey-Serres, 1993 Nuc. Acids Res., 21, 5294-5300. PCR with suitable primers was used to amplify from the full length ORF. The following ORFs were built:

S-peptide:

i. An ORF for the S-peptide containing a methionine translation initiation codon followed by codons 1 to 15 of the mature RNaseA sequence (see Figures 4A and 4B) and terminated by an Ochre stop codon.

ii. An ORF made of a methionine translation initiation codon followed by codons 1 to 15 of the mature RNaseA sequence, followed by a linker sequence encoding (Gly4-

Ser)3 (see Figures 4A and 4B). This gene was designed so that it can be fused in frame to the ORF of the GUS protein by cloning in the BamHI site of plasmid p2027 which contains the GUS gene from pBI101.3 (Jefferson, 1987 Plant Mol.Biol.Reporter, 5 387-405).

iii. A translational fusion comprising the ORF of the mitochondrial protein targeting sequence of AOX3 protein from soybean (Finnegan and Day, 1997, Plant Physiol. 114, pp455) and the ORF of S-peptide as described in (i) but lacking the methionine translation initiation codon (Figure 4C). The gene product of said translational fusion shows the S-peptide fused to the C-terminal end of the targeting sequence.

iv. A translational fusion comprising the ORF of the mitochondrial protein targeting sequence of AOX3 protein (supra) and the ORF of the S-peptide-GUS fusion as described in (ii) but lacking the methionine translational initiation codon (Figure 4C). The gene product of said translational fusion shows that the S-peptide-GUS protein fused to the C-terminal end of the targeting sequence.

25 S-protein:

i. An ORF for the "S-protein +5", which contains a methionine translation initiation codon followed by codons 16 to 124 of mature RNaseA sequence and is terminated by an Ochre codon.

30 ii. An ORF for the S-protein which contains a methionine translation initiation codon followed by codons 21 to 124 of mature RNaseA sequence and is terminated by an Ochre codon.

iii. A translational fusion comprising the ORF of the mitochondrial protein targeting sequence of AOX3 protein (supra) and the ORF of the S-protein as described in
5 (ii) but lacking the methionine translational initiation codon (Figure 4C). The gene product of said translational fusion shows the S-protein fused to the C-terminal end of ubiquitin.

10 iv. A translational fusion comprising genomic DNA encoding ubiquitin and the ORF of the S-protein as described in (ii) but lacking the methionine translational initiation codon (Figure 4C). The gene
15 product of said translational fusion shows the S-protein fused to the C-terminus of ubiquitin.

Genes under control of the A9 promoter were then built and introduced into plants as in Example 2.

20 In Fig. 3A: The sequences encoding the S-peptide, the S(+5)-protein and the S-protein were constructed by first aligning sense oligonucleotides RN-I to RN-VII (lanes 2, 5, 7, 9, 11, 13, 16) along complementary guide oligonucleotides RN-1 to RN-6 (lanes 3, 6, 8, 10, 12,
25 14) and then selectively ligating the correctly aligned sense oligonucleotides using Taq-DNA-Ligase.

The ligation resulted in a continuous single DNA strand (sense) which was subsequently amplified by Vent DNA
30 polymerase (25 PCR cycles) using one of two primer pairs as follows: (i) Primers RN-a (lane 1) and RN-b (lane 15) amplified the full ligation product. The PCR product was gel purified and cleaved with restriction enzymes BamHI (underlined, lanes 1 and 15) and BgIII underlined,

lanes 2 and 4) to yield two DNA fragments encoding the S-peptide and the S(+5) protein. The two fragments were cloned separately into the BamHI site downstream of the pA9 promoter in plasmid p1415 to yield plasmids p4837 (S-peptide) and p4838 (S+5 protein). (ii) Primers RN-d (lane 4) and RN-b (lane 15) amplified the coding sequence of the S-protein. The PCR product was cloned as described in (i) to yield plasmid p4839 (S-protein).

- 10 lane 1: PCR primer (sense) RN-a
lane 2: Oligonucleotide RN-I and alignment to oligonucleotide RN-II
lane 3: Guide oligonucleotide RN-1 (antisense)
lane 4: PCR primer (sense) RN-d
15 lane 5: Oligonucleotide RN-II (continued from lane 2) and alignment to oligonucleotide RN-IIIN
lane 6: Guide oligonucleotide RN-2N (antisense)
lane 7: oligonucleotide RN-IIIN (continued from lane 5) and alignment to oligonucleotide RN-IV
20 lane 8: Guide oligonucleotide RN-3 (antisense)
lane 9: oligonucleotide RN-IV (continued from lane 7) and alignment to oligonucleotide RN-V
lane 10: Guide oligonucleotide Rn-4 (antisense)
lane 11: oligonucleotide RN-V (continued from lane 9) and alignment to oligonucleotide RN-VI
25 lane 12: Guide oligonucleotide RN-5 (antisense)
lane 13: oligonucleotide RN-VI (continued from lane 11) and alignment to oligonucleotide RN-VII
lane 14: Guide oligonucleotide Rn-6 (antisense)
30 lane 15: PCR primer (antisense) RN-b
lane 16: oligonucleotide RN-VII (continued from lane 13)

Symbols:

(5'): non-phosphorylated 5' end

(5P): phosphorylated 5' end

(30H): conventional 3' end

- 5 (small letters): bases added for the convenience of cloning.

10 In Fig. 3B: The sequences encoding the S-peptide with the (Gly₄Ser)₃-linker peptide were constructed by first aligning sense oligonucleotides RN-I and RN-VIII (lanes 2 and 4) along the complementary guide oligonucleotide RN-7, and then selectively ligating the correctly aligned oligonucleotides using Taq-DNA-Ligase.

- 15 The ligation resulted in a continuous single DNA strand which was subsequently amplified by Vent DNA polymerase (25 PCR cycles) using the primer pair RN-a (lane 1) and RN-c (lane 5). This PCR reaction yielded the full length, double stranded ligation product. The PCR
20 product was gel purified, then cleaved with restriction enzymes BamHI (underlined, lane 1) and BglII (underlined, lane 5) and cloned into the BamHI site of p2027 to generate an NH₂-terminal protein fusion to GUS under the control of the pA9 promoter (p2027 was
25 constructed by cloning the GUS coding sequence of pBI101.3 as a BamHI/SmaI fragment into the BamHI site of p1415). This yielded plasmid p2028.

- lane 1: PCR primer (sense) RN-a
30 lane 2: Oligonucleotide RN-I encoding the S-peptide as in Figure 3a and the alignment to oligonucleotide RN-VIII encoding the (Gly₄-Ser)₃ linker peptide
lane 3: Guide oligonucleotide (antisense) RN-7

lane 4: Oligonucleotide RN-VIII (continued from lane 2)

lane 5: PCR primer (antisense) RN-c

5 Symbols:

(5'): non-phosphorylated 5' end

(5P): phosphorylated 5' end

(30H): conventional 3' end

10 (small letters): bases added for the convenience of cloning

In Figure 4A: The protein and DNA sequence is shown for S-peptide and the S-peptide with (Gly4 Ser)3 linker. The S-peptide linker sequence was fused in frame to GUS
15 to yield plasmid p2028 as described for Figure 3B.

In Figure 4B: The ORF for (S+5)-protein and S-protein is shown as contained in plasmids p4838 and p4839, respectively. These plasmids were described above for
20 Figure 3A.

In Figure 4C:

(i) The mitochondrial protein targeting sequence (short of the last four amino acids: Leu-Arg-Arg-Met) was
25 obtained by PCR with primers AOX3MI1 and AOX3MI2 from a plasmid which contained the cDNA of Alternative Oxidase (AOX3) of soybean as published by Finnegan and Day, 1997 (Plant Physiol. 114, pp455). Restriction sites (XbaI and BglII at the 5' end and AflII and BamHI at the 3'
30 end) were introduced during the thermocycling to yield the PCR product which was cloned XbaI/BamHI downstream of the A9 promoter in p1415. This plasmid was called p0200.

(ii) Primers SPEPMI1 and SPEPMI2 were then used to produce from plasmid p4837 a PCR fragment encoding within and downstream of an AflII restriction site the missing four amino acids (Leu-Arg-Arg-Met) of the mitochondrial targeting signal followed by the ORF of S-peptide. A PCR generated BamHI site at the 3' end allowed cloning of the PCR fragment as an AflII/BamHI fragment into p0200. This cloning yielded plasmid p0203, containing the complete ORF of the translational fusion as shown.

(iii) The translational fusion of mitochondrial targeting sequence and ORF of S-peptide-GUS was generated in a similar fashion as described in (ii) except that PCR primers SPEPMI1 and SPEPMI2 were used on template p2028 to generate an AflII/BamHI fragment that was cloned into p0200 to yield p0204.

(iv) The translational fusion of mitochondrial targeting sequence and ORF of S-protein was generated in a similar fashion as described in (ii and iii), except that PCR primers SPROTMI1 and SPROTMI2 were used on template p4838 to generate an AflII/BamHI fragment that was cloned into p0200 to yield p0202.

(v) A PCR fragment was generated from template p4839 with primers SPROTF and SPROTR containing the ORF of S-protein in between BamHI restriction sites at either end. After digestion with BamHI this PCR fragment was cloned into the BamHI site of p3245 which yielded the translational fusion in p3249 of genomic ubiquitin DNA and S-protein as shown.

EXAMPLE 4

Use of the Dimer Protein Apetala3-Pistillata

5 Apetala3 (Ape3) and Pistillata (Pi) are two proteins of
Arabidopsis thaliana which are involved in the
regulation of floral differentiation. The genes are
known while the endogenous pattern of expression in the
tapetum is not known. Expression of the Arabidopsis
10 genes in the maize tapetum leads to disruption of the
normal anther development by activating normally silent
genes. These genes can also be used to activate, in the
maize tapetum, an Arabidopsis promoter responsive to the
Ap3-Pi dimer such as the Ap3 promoter (pAp3) itself.

15 We have built the following genes:

pA9-Apetala3

The cDNA for Ap3 (Jack et al, 1992, Cell 68, 683-697
GenBank Accession No. M86357) was cloned in the A9
20 expression cassette of pWP91 (WO-A-9211379) giving
plasmid p4796. This plasmid contains the Ap3 cDNA with
approximately 15 bases of 5' untranslated sequence
followed by the whole ORF (698 bases from ATG to TAA)
followed by approximately 120 bases of 3' untranslated
25 sequence, cloned in the BamHI site of pWP91.

pA9-Pistillata

The cDNA for Pi (Goto and Meyerowitz, 1994, Genes Dev.
8, 1548-1560 GenBank Accession No. D30807) was cloned in
30 the A9 expression cassette of pWP91 (WO-A-9211379)
giving plasmid p0180. This plasmid contains the Pi cDNA
with approximately 24 bases of 5' untranslated sequence
followed by the whole ORF (626 bases from ATG to TGA)
followed by approximately 250 bases of 3'untranslated

sequence, cloned in the XbaI-BamHI sites of pWP91.

pApetala3-PRGlucanase

5 The A9 promoter sequence in plasmid A9PR (described in
Worrall et al, 1992, The Plant Cell, 4, 759-771) was
replaced by a 1250 bp (approx) sequence containing the
Ap3 promoter region, obtained by PCR amplification of
10 *Arabidopsis thaliana* genomic DNA, according to the
published sequence (Jack et al, 1994 Cell, 76, 703-716),
giving plasmid p4817.

15 The genes were introduced in maize in various
combinations, by biolistic transformation techniques
known in the art. Plants were regenerated and assessed
for male fertility.

-p4796 (pA9-Ap3)/p0180 (pA9-Pi) cause male sterility.
Neither of them alone causes male sterility.
-p4796/p0180/p4817 (pAp3-PRGlucanase) cause sterility,
20 when p4817 with only one of the two transcription factor
genes does not.

CLAIMS

1. A pair of parent plants for producing seeds comprising:

5

(i) a first parent plant containing one or more gene sequences encoding a polypeptide or protein A; and

10

(ii) a second parent plant containing one or more gene sequences encoding a polypeptide or protein B;

wherein the polypeptides A, B, when expressed in separate plants, do not form an active enzyme, a regulatory protein or protein which affects the functionality and/or viability and/or the structural integrity of a cell, but when expressed in the same plant do form an active enzyme, regulatory protein, or protein which affects the structural integrity of a cell.

20

2. A pair of plants as claimed in claim 1 wherein the one or more gene sequences from at least one of the parents is transgenic.

25

3. A pair of plants as claimed in claim 1 or claim 2 wherein the polypeptides or proteins A, B, when expressed in the same plant, cause cell ablation, especially male-sterility or embryoless seeds.

30

4. A pair of plants as claimed in any one of claims 1 to 3 wherein one of the parent plants is male-sterile.

5. A pair of plants as claimed in any one of claims 2

to 4 wherein the one or more gene sequences encoding both or one of the polypeptides or proteins A, B, is operatively linked to a tissue specific promoter.

5 6. A pair of plants as claimed in any one of claims 1 to 5 wherein the polypeptides A, B are naturally occurring subunits of the protein complex of an active enzyme, regulatory protein, or protein which affects the structural integrity of a cell.

10

7. A pair of plants as claimed in claim 6 wherein the polypeptides A, B are two polypeptide subunits of an enzyme having RNase activity such as the enzyme Barnase or RNase A or the monomers of the protein complex of the
15 Apelata3-pistillata.

8. A pair of plants as claimed in any one of claims 1 to 5 wherein the polypeptides A, B are artificially split polypeptides of an active enzyme, regulatory
20 protein or protein which affects the structural integrity of a cell.

9. A pair of plants as claimed in any one of the preceding claims wherein each parent plant is homozygous
25 with respect to the one or more gene sequences encoding polypeptide A or B respectively.

10. A pair of plants as claimed in any one of claims 3 to 9 wherein the cause of male-sterility is direct or
30 indirect.

11. A pair of plants as claimed in any one of claims 5 to 10 wherein the tissue-specific promoter is a tapetum-specific promoter, an embryo-specific promoter or a seed

specific promoter.

12. A pair of plants as claimed in any one of claims 1
to 11 wherein one or both of the polypeptides or
5 proteins is fused to a carrier protein and/or a protein
targeting signal.

13. A pair of plants as claimed in any one of claims 1
to 12 wherein each polypeptide or protein A, B is linked
10 to a protein dimerisation domain of a dimeric or
multimeric protein sequence that promotes association of
between subunits A and B.

14. A pair of plants as claimed in any one of the
15 preceding claims wherein the one or more gene sequences
from at least one of the parent plants is a heterologous
gene sequence.

15. A method for producing a plant having a desired
20 phenotype by virtue of an active enzyme, a regulatory
protein or a protein which affects the structural
integrity of a cell, the method comprising crossing a
first line with a second line wherein the first line
contains one or more gene sequences encoding a
25 polypeptide or protein but which line does not have the
desired phenotype and wherein the second line contains
one or more gene sequences encoding a polypeptide or
protein B which is complementary to the polypeptide or
protein A but which line does not have the desired
30 phenotype.

16. A method as claimed in claim 15 wherein the one or
more gene sequences from at least one of the lines is
transgenic.

17. A method as claimed in claim 15 or claim 16 wherein desired phenotype is cell ablation especially male-sterility or embryoless seeds.

5

18. A method as claimed in any one of claims 15 to 17 wherein one of the lines is male-sterile.

10 19. A method as claimed in any one of claims 15 to 18 wherein the one or more gene sequences encoding polypeptides or protein A and/or B is operatively linked to a tissue-specific promoter.

15 20. A method as claimed in any one of claims 15 to 19 wherein the polypeptides or proteins A, B are naturally occurring subunits of an active enzyme, regulatory protein or protein which affects the structural integrity of a cell.

20 21. A method as claimed in claim 20 wherein the polypeptides or proteins A, B are two polypeptide subunits of an enzyme having RNase activity such as the enzyme Barnase, RNase A or the subunits of the protein *Apelata3-pistillata*.

25

22. A method as claimed in any one of claims 15 to 19 wherein the polypeptides or proteins A, B are artificially split polypeptides of an active enzyme, regulatory protein or protein which affects the
30 structural integrity of a cell.

23. A method as claimed in any one of claims 15 to 22 wherein each line is homozygous with respect to the gene sequence encoding polypeptide or protein A, B,

respectively.

24. A method as claimed in any one of claims 15 to 23
wherein the desired phenotypic trait is direct or
5 indirect male-sterility.

25. A method as claimed in any one of the claims 15 to
24 wherein the tissue-specific promoter is a tapetum-
specific promoter, an embryo-specific promoter or a seed
10 specific promoter.

26. A method as claimed in any one of claims 15 to 25
wherein one or both of the polypeptides or proteins A, B
is fused to a carrier protein and/or a protein targeting
15 signal.

27. A method as claimed in any one of claims 15 to 26
wherein each polypeptide or protein A, B is linked to a
different protein dimerisation domain of a dimeric or
20 multimeric protein.

28. A method as claimed in any one of claims 15 to 27
wherein at least one of the lines contains, as the one
or more gene sequences, heterologous gene sequences.

25

29. A seed or plant obtainable from a pair of plants as
claimed in any one of claims 1 to 14 or by a method as
claimed in any one of claims 15 to 28.

30. A seed or plant, having a phenotype of an active
enzyme, regulatory protein or protein which affects the
integrity of a cell, which is caused by the combined
action of two or more transgenes, not present on the
same copy of a chromosome.

PROTEIN COMPLEMENTATION IN TRANSGENIC PLANTS

Abstract of the Disclosure

5 The invention relates to pairs of parent plants for
producing hybrid seeds and to methods for producing plants
with a desired phenotype. The desired phenotype is an
active enzyme, a regulatory protein or a protein which
affects the functionality and/or viability and/or
structural integrity of a cell. Preferably, the desired
10 phenotype is substantially absent from the parent
plants/lines. In particular, the invention relates to
parent plants and methods involving plant lines for
producing male-sterile plants and seeds.

FIG. 1A

Barnase coding sequence

```

1 met ala gln val ile asn thr phe asp gly val ala asp tyr leu gln thr tyr
2 TCTAGACC ATG GCA CAG GTT ATC AAC ACG TTT GAC GCG GTT CCG GAT TAT CTT CAG ACA TAT
3 3'gttcattgagatctgg tac 5' (B1 primer)

1 his lys leu pro asp asn tyr ile thr lys ser glu ala gln ala leu gly trp
2 CAT AAG CTA CCT GAT AAT TAC ATT ACA AAA TCA GAA GCA CAA GCC CTC GGC TGG
3 (B4 primer) 3' t gtt cgg gag ccg acc5'

1 val ala ser lys gly asn leu ala asp val ala pro gly lys ser ile gly gly
2 GTG GCA TCA AAA GGG AAC CTT GCA GAC GTC GCT CCG GCG AAA AGC ATC GGC GGA
3 5'gca tca aaa ggg aac c 3' (B2 primer)

1 asp ile phe ser asn arg glu gly lys leu pro gly lys ser gly arg thr trp
2 GAC ATC TTC TCA AAC AGG GAA GGC AAA CTC CCG GGC AAA AGC CGA ACA TGG
3

1 arg glu ala asp ile asn tyr thr ser gly phe arg asn ser asp arg ile leu
2 CGT GAA GCG GAT ATT AAC TAT ACA TCA GGC TTC AGA AAT TCA GAC CCG ATT CTT
3

1 tyr ser ser asp trp leu ile tyr lys thr thr asp his tyr gln thr phe thr
2 TAC TCA AGC GAC TGG CTG ATT TAC AAA ACA ACG GAC CAT TAT CAG ACC TTT ACA
3

1 lys ile arg OCH
2 AAA ATC AGA taa
3

```

FIG. 1B

Intergenic sequence

```

CGAAAAAACGGCTTCCTGCGGAGCGCTTTTTCAGCTTTACATAAAGTGTGTAATAAATTTTCTTCAAACCTCTGATCGGTCAATTT
CACTTTCGGATCCGTCCTCAATCTGCACCGTCCGAGACAGGAGACATCGTCCAGCTGAACCGGGCAGAAATCCGGCCATTTCTGAAG
AGAAAAATGGTAACTGATAGATAAAATCATAAGAAAGGAGCCGCAC

```

FIG. 1C

Barstar coding sequence

```

1 Met lys lys ala val ile asn gly glu gln ile arg ser ile ser asp leu his
2 ATG AAA AAA GCA GTC ATT AAC GCG GAA CAA ATC AGA AGT ATC ACC GAC CTC CAC
3
1 gln thr leu lys lys glu leu ala leu pro glu tyr tyr gly glu asn leu asp
2 CAG ACA TTG AAA AAG GAG CTT GCC CTT CCG GAA TAC TAC GGT GAA AAC CTG GAC
3
1 ala leu trp asp cys leu thr gly trp val glu tyr pro leu val leu glu trp
2 GCT TTA TGG GAT TGT CTG ACC GGA TGG GTG GAG TAC CCG CTC GTT TTG GAA TGG
3
1 arg gln phe glu gln ser lys gln leu thr glu asn gly ala glu ser val leu
2 AGG CAG TTT GAA CAA ACC AAG CAG CTG ACT GAA AAT GGC GCC GAG AGT GTG CTT
3
1 gln val phe arg glu ala lys ala glu gly cys asp ile thr ile ile leu ser
2 CAG GTT TTC CGT GAA GCG AAA GCG GAA GCG TGC TGC GAC ATC ACC ATC ATA CTT TCT
3
1 OCH
2 TAA TACGATCAATGGGAGATGAACAATATAGATCCCCCGGGCTGCAGGAATTC
3 5'taa tacgatcaatgggagatg 3' (B3 primer)

```

- 1: Translation of DNA sequences encoding Barnase (A) and Barstar (C), respectively
- 2: DNA sequence encoding either Barnase (A), Barstar (C) or the synthetic intergenic region (B) according to Paul et al. (1992)
- 3: Sequence of DNA primers that were used for IPCR to construct pepA* (B3/B4) and pepB* (B1/B2).

FIG. 1D

Translational fusion of
ORF Peptide A**/ (Gly4 ser)3 Linker peptide / GUS

met ala gln val ile asp thr phe asp gly val ala asp tyr leu gln thr tyr his lva
tctagacc ATG GCA CAG GTT ATC AAC ACG TTT GAC GCG GTT GCG GAT TAT CTT CAG ACA TAT CAT AAG

leu pro asp asp tyr ile thr lva ser glu ala gln ala leu gly tyr met gly gly gly
CTA CCT GAT AAT TAC ATT ACA AAA TCA GAA GCA CAA GCC CTC GGC TCG ATG GGC GGT GGC

gly ser gly gly gly ser gly gly gly ser gly ile pro gly tyr gly gln ser
GGT TCC GGT GGC GGT GGC AGC GGC GGC GGT GGT AGC GCG atc ccc ggg tac ggt cag tcc

pro met
ctt atg ... of GUS

Underlined: ORF of peptide A**

FIG. 1E

Nucleotide Sequence of Translational fusion of
Ubiquitin genomic sequence and ORF Peptide A***

tctagacc ATGCAGATCT TCGTGAAAAC CTTGACCGGC AAGACCATCA CTCTCGAGGT CGAGAGCAGC GACACCATCG
ACAATGTCAA GGCCAGATC CAAGACAAAG AAGGTATCAT TCTTCTTCAG TCAATCTGGA TTCTTCTCTT TAGCTTTTTC
AAATTTCAGAT CTCTTATCAT TTACTTGTCTT CTCCTTTAAG GAATCCCTCC GGATCAGCAG AGATTGATCT TCGCCGGA
GCAGCTCGAA GATGCCGTA CTTTGGCTGA CTACACATC CAGAAAGTA CGAATCATC CGAATCCTTC TGTGATCAT
TTGATGATC TGATGTATA AACTCTAATG GATTGTATC ATTGTTAAAC AGAATCTACA CTTTCATCTTG TGTGAGGCT
TAGAGGTGGA GCACAGGTTA TCAACACGTT TGACGGGGTT GCGGATTATC TTCAGACATA TCATAAGCTA CCTGATAATT
ACATTACAAA ATCAGAAGCA CAAGCCCTCG GCTGATGTA Gaggatccc

Underlined: Introns A and B within the ubiquitin sequence.
Bold: glycine codon 76 at the end of the ubiquitin ORF

FIG. 1F

Nucleotide Sequence of Translational fusion of Ubiquitin genomic sequence and ORF Peptide B***

tctagacc ATGCAGATCT TCGTGAAAC CTTGACCGC AAGACCATCA CTCTCGAGT CGAGAGCAGC GACACCATCG
ACAATGTCAA GGCCAGATC CAAGACAAG AAGTATCAT TCTTCTCAG TCAATCTGGA TTCTTCTCTT TAGCTTTTIG
AAATCAGAT CTCTATCAT TTACTTGTTT CTCTTFAAG GAATCCCTCC GGATCAGCAG AGATTGATCT TCGCCCGAAA
GCAGCTCGAA GATGJCCGTA CTTTGGCTGA CTACAACATC CAGAAAGTGA CGAATCATC CGAATCCTTC TGTGATCAT
TTGATGATC TGATGTATA AACTCTAATG GATGTATC ATTGTAAAC AGAATCTACA CTTCATCTTG TGTGAGCGT
TAGAGGTGGA GCATCAAAAG GGAACCTTC AGAGTCGCT CCGGGGAAA GCATCGCGG AGACATCTTC TCAAAACAGGG
AAGGCAACT CCGGGGAAA AGCGAGCAA CATGGCTGA AGCGATAT AACTATACAT CAGGCTTACG AAATTCAGAC
CGATTCTTT ACTCAAGCA CTGGCTGATT TACAAACAA CGACCATTA TCAGACCTTT ACAAAATCA GATAA...

Underlined: Introns A and B within the ubiquitin sequence.
Bold: glycine codon 76 at the end of the ubiquitin ORF

FIG. 1G

DNA sequence of I PCR primers (example 1)

B5	5'	CACAAGTACTCTAGACCATG 3'	(forward)
B6	5'	CATCCAGCCGAGGGCTTGT 3'	(reverse)
B7	5'	GGCGGTGGCGGTTCCG 3'	(forward)
B8	5'	CCACTAGTTCTAGAGTACTTGTG 3'	(reverse)
B9	5'	GCACAGGTTATCAACACG 3'	(forward)
B10	5'	GCGGATCCTCTACATCCAGCCGAGGGCTTGT 3'	(reverse)
B11	5'	GCATCAAAAGGGAACC 3'	(forward)
B12	5'	GGTCTAGAGTACTTGTG 3'	(reverse)
Ubq16F	5'	GCTCTAGACCATGCAGATCTTCGTGAAAC 3'	(forward)
Ubq1R	5'	CTGGATCCACCTCTAAGCCTCAACA 3'	(reverse)
Ubq1a	5'	TATGGATCCCCCGGCTGCAGGAA 3'	(forward)
Ubq1b	5'	TCCACCTCTAAGCCTCAACAC 3'	(reverse)

FIG. 2
SCHEMATIC ILLUSTRATION OF pepA* AND pepB*
CONSTRUCTION BY INVERSE PCR (IPCR)




FIG. 3A

In Vitro Construction from Synthetic Oligonucleotides of S-peptide, S(+5)-protein and S-protein

1. 5'-gcggatccatgaaggagaccgcc-3OH
2. 5'-gcggatccatgaaggagaccgccgcccgaagtgcaggccgacacatggacagc-3OH 5P-TAAAGATCTATG...
3. 3OH-GTACCTGTGCG_____ATTCTAGATAC-5'
4. 5'-ccagatctatg----AGCTCCTCCAACACTAG-3OH
5. ...AGCACCTCCGCCGCCAGCTCCTCCAACACTGATGAAGTCT-3OH 5P-AGGAACCTGA...
6. 3OH-ACTACTTCAGA_____TCCTTGGACT-5'
7. ...CCAAGGACAGGTGCAAGCCAGTCAACACCTTTCGTCCACGAGAGCCTGGC-3OH 5P-CGATGTCCAG...
8. 3OH-CTCGGACCG_____GCTACAGGTC-5'
9. ...GCCGTCTGCAGCCAGAGAAGCGTGGCCTGCAAGAACGG-3OH 5P-TCAGACCAACT...
10. 3OH-CGTCTTTGCC_____AGTCTGGTTGA-5'
11. ...GCTACCAGTCTACAGCACCATGTCCATCACCGACTGCCGCGAGACCGG-3OH 5P-CTCCAGCAAG...
12. 3OH-GCTCTGGCC_____GAGTCTGTTTC-5'
13. ...TACCCTAACTGCGCCTACAAGACCACCAGGCCAACAAAGCACATC-3OH 5P-ATTGTTCCTTG...
14. 3OH-GTTCTGTAG_____TAACAACGGAC-5'
15. 3OH-CTGCGGAGGCAGATTtcctagggc-5'
16. ...CGAGGGTAACCCCTTACGTGCCTGTCCACTTCGACGCCCTCCGTCTAAaggatcccg-3OH

FIG. 3B

In Vitro Construction from Synthetic Oligonucleotides of the Sequence encoding the S-peptide and the (Gly4-Ser)3 Linker

- [illegible]

Protein and DNA Sequences of S-peptide and S-peptide with (Gly4 Ser)3 linker

[illegible]

Legend to Figure 4 A:

- 1: DNA sequence of the synthetic Bovine RNase A gene (codon 1 to 15) according to N. Vasantha and David Filpula (1989)
- 2: Translation of synthetic DNA sequences encoding Bovine RNase A
- 3: DNA sequence of the S-peptide coding sequence referred to in this invention
- 4: DNA sequence encoding the S-peptide with (gly4 ser)3 linker peptide referred to in this invention

FIG. 4B

Protein and DNA Sequences of S(+5)-protein and S-protein

1	---	AGC	ACC	AGT	GCT	GCC	AGT	TCT	TCC	AAC	TAC	TGT	AAC	CAG	ATG	ATG	ATG	AAG	TCT	AGA	AAC	TTG	ACC	AAG
2	met	ser	thr	ser	ala	ala	ser	ser	ser	asn	tyr	cys	asn	gln	met	met	lys	ser	arg	asn	leu	thr	lys	
3	agatct	atg	ACC	tcc	gcc	GCC	agc	tcc	TCC	AAC	TAC	tgc	tgc	AAC	CAG	ATG	ATG	AAG	TCT	agg	AAC	ctg	ACC	AAG
4	agatct	atg	---	---	---	---	agc	tcc	TCC	AAC	TAC	tgc	tgc	AAC	CAG	ATG	ATG	AAG	TCT	agg	AAC	ctg	ACC	AAG
1		GAC	AGA	TGT	AAG	CCA	GTT	AAC	ACA	TTT	GTC	CAC	GAG	AGT	TTG	GCT	GAT	GTC	CAA	GCC	GTC	TGC	AGT	
2		asp	arg	cys	lys	pro	val	asn	thr	phe	val	his	glu	ser	leu	ala	asp	val	gln	ala	val	cys	ser	
3		GAC	agg	tgc	AAG	CCA	gtc	AAC	acc	tcc	GTC	CAC	GAG	agc	ctg	gcc	GAT	GTC	cag	GCC	GTC	TGC	agc	
4		GAC	agg	tgc	AAG	CCA	gtc	AAC	acc	tcc	GTC	CAC	GAG	agc	ctg	gcc	GAT	GTC	cag	GCC	GTC	TGC	agc	
1		CAG	AAA	AAC	GTT	GCA	TGC	AAG	AAC	GGT	CAA	ACG	AAC	TGT	TAC	CAG	AGT	TAC	AGC	ACC	ATG	TCC	ATC	
2		gln	lys	asn	val	ala	cys	lys	asn	gly	gln	thr	asn	cys	tyr	gln	ser	tyr	ser	thr	met	ser	ile	
3		CAG	aag	AAC	gtg	gcc	TGC	AAG	AAC	GGT	cag	acc	AAC	tgc	TAC	CAG	tcc	TAC	agc	ACC	ATG	TCC	ATC	
4		CAG	aag	AAC	gtg	gcc	TGC	AAG	AAC	GGT	cag	acc	AAC	tgc	TAC	CAG	tcc	TAC	agc	ACC	ATG	TCC	ATC	
1		ACT	GAC	TGT	CGT	GAG	ACA	GGC	TGC	AGC	AAG	TAT	CCT	AAT	TGT	GCT	TAC	AAG	ACC	ACA	CAG	GCG	AAC	
2		thr	asp	cys	arg	glu	thr	gly	ser	ser	lys	tyr	pro	asn	cys	ala	tyr	lys	thr	thr	gln	ala	asn	
3		acc	GAC	tgc	cgc	GAG	acc	GGC	tcc	AGC	AAG	tac	CCT	aac	tgc	gcc	TAC	AAG	ACC	acc	CAG	gcc	AAC	
4		acc	GAC	tgc	cgc	GAG	acc	GGC	tcc	AGC	AAG	tac	CCT	aac	tgc	gcc	TAC	AAG	ACC	ACA	CAG	gcc	AAC	
1		AAA	CAC	ATC	ATT	GTT	GCT	TGT	GAA	GGT	AAC	CCT	TAC	GTT	CCT	GTC	CAC	TTT	GAC	GCC	AGT	GTT	TAA	
2		lys	his	ile	ile	val	ala	cys	glu	gly	asn	pro	tyr	val	pro	val	his	phe	asp	ala	ser	val	OCH	
3		aag	CAC	ATC	ATT	GTT	gcc	tgc	gag	GGT	AAC	CCT	TAC	gtg	CCT	GTC	CAC	ttc	GAC	GCC	tcc	gtc	TAA	
4		aag	CAC	ATC	ATT	GTT	gcc	tgc	gag	GGT	AAC	CCT	TAC	gtg	CCT	GTC	CAC	ttc	GAC	GCC	tcc	gtc	TAA	
1		-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	
2		-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	
3		agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	
4		agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	agatcc	

Legend to Figure 4 B:

- 1: DNA sequence of the synthetic RNase A gene (codons 16 to 124) according to Vasanth and Filpula (1989)
- 2: Translation of DNA sequences encoding the Bovine RNase A
- 3: DNA sequence of the synthetic S(+5)-protein coding sequence (aa16 to aa124)
- 4: DNA sequence of the synthetic S-protein coding sequence (aa21 to aa124)

FIG. 4C

10 / 12

i. PCR amplification product encoding impartial AOX3 targeting signal

XbaI / BglII

cctagatccttaac ATGAAGAATG TTTTAGTAAG GTCAGCTGCG CGAGCTCTGC TTGGCGGCGG
TGGGCGGAGC TACTACCGCC AGCTCTCAAC GCGGCGGATC GTGGAACAGA
GACACCAGCA CCGTGGCGGC GCGTTTGAA GCTTCCA ccttaagcggatcc
AflIII / BamHI

ii. ORF encoding AOX3 targeting sequence (underlined) and S-peptide

ATGAAGAATG TTTTAGTAAG GTCAGCTGCG CGAGCTCTGC TTGGCGGCGG TGGGCGGAGC
TACTACCGCC AGCTCTCAAC GCGGCGGATC GTGGAACAGA GACACCAGCA CGGTGGCGGC
GCGTTTGAA GCTTCCACTT AAGAAGGATG AAGGAGACCG CCGCCGCCAA GTTCGAGCGC
CAGCACATGG ACAGCTAA

iii. ORF encoding AOX3 targeting sequence (underlined) and S-peptide-(Gly4 Ser)3-GUS

ATGAAGAATG TTTTAGTAAG GTCAGCTGCG CGAGCTCTGC TTGGCGGCGG TGGGCGGAGC
TACTACCGCC AGCTCTCAAC GCGGCGGATC GTGGAACAGA GACACCAGCA CGGTGGCGGC
GCGTTTGAA GCTTCCACTT AAGAAGGATG AAGGAGACCG CCGCCGCCAA GTTCGAGCGC
CAGCACATGG ACAGCGGCGG TGGCGGTTCC GGTGGCGGTG GCAGCGGCGG CCGTGGTAGC
GGGATCCCCG GGTACGGTCA GTCCCTTATG --> GUS

iv. ORF encoding AOX3 targeting sequence (underlined) and S-protein

ATGAAGAATG TTTTAGTAAG GTCAGCTGCG CGAGCTCTGC TTGGCGGCGG TGGGCGGAGC
TACTACCGCC AGCTCTCAAC GCGGCGGATC GTGGAACAGA GACACCAGCA CGGTGGCGGC
GCGTTTGAA GCTTCCACTT AAGAAGGATG AGCTCCTCCA ACTACTGCAA CCAGATGATG
AAGTCTAGGA ACCTGACCAA GGACAGGTGC AAGCCAGTCA ACACCTCCGT CCACGAGAGC
CTGGCCGATG TCCAGGCCGT CTGCAGCCAG AAGAACGTGG CCTGCAAGAA CCGTCAGACC
AACTGCTACC AGTCCTACAG CACCATGTCC ATCACCAGCT GCCGCGAGAC CCGCTCCAGC
AAGTACCCTA ACTGCGCCTA CAAGACCACA CAGGCCAACA AGCACATCAT TGTTCCTGTC
GAGGGTAACC CTTACGTGCC TGTCCACTTC GACGCCTCCG TCTAA

v. Translational fusion of Ubiquitin genomic sequence and ORF of S-protein

ATGCAGATCT TCGTGAAAAC CTTGACCGGC AAGACCATCA CTCTCGAGGT CGAGAGCAGC
GACACCATCG ACAATGTCAA GGCCAAGATC CAAGACAAAG AAGGTATCAT TCTTCTCTCAC
TCAATCTGGA TTCTTCTCTT TAGCTTTTTG AAATTTCAGAT CTCTTATCAT TTACTTGTCT
CTCCTTTAAG GAATCCCTCC GGATCAGCAG AGATTGATCT TCGCCGGA GCAGCTCGAA
GATGGCCGTA CTTTGGCTGA CTACAACATC CAGAAAGGTA CGAAATCATC CGAATCCTTC
TGTTGATCAT TTGATGATC TGATTGTATA AAGTCTAATG GATTGTTATC ATTTGTAAAC
AGAATCTACA CTTTATCTTG TGTGAGGCT TAGAGGtGGa tcCagCTCCA ACTACTGCAA
CCAGATGATG AAGTCTAGGA ACCTGACCAA GGACAGGTGC AAGCCAGTCA ACACCTCCGT
CCACGAGAGC CTGGCCGATG TCCAGGCCGT CTGCAGCCAG AAGAACGTGG CCTGCAAGAA
CGGTGAGACC AACTGCTACC AGTCCTACAG CACCATGTCC ATCACCAGCT GCCGCGAGAC
CGGCTCCAGC AAGTACCCTA ACTGCGCCTA CAAGACCACA CAGGCCAACA AGCACATCAT
TGTTCCTGTC GAGGGTAACC CTTACGTGCC TGTCCACTTC GACGCCTCCG TCTAA

Underlined: introns A and B within the ubiquitin encoding sequence

Bold: codon for Glycine⁷⁶, marking the C-terminus of the ubiquitin.


Small letters: PCR introduced conservative codon changes to generate a BamHI site and to modify the codon usage

FIG. 4D

Nucleotide sequence of T PCR primers (example 3)

Sprot F	5 ' GGTGGATCCAGCTCCAACTACTGCAAC 3 '
Sprot R	5 ' CGGGATCCTTAGACGGAGGCGTCG 3 '
SprotMI1	5 ' GTCCTTAAGAAGGATGAGCTCCTCCAACTAC 3 '
SprotMI2	5 ' CGGGATCCTTAGACGGAGGCGTCG 3 '
SpepMI1	5 ' GTCCTTAAGAAGGATGAAGGAGACCGCCG 3 '
SpepMI2	5 ' TCGGGATCCTTAGCTGTCCATGTGCTG 3 '
SpepGMI2	5 ' TCGGGATCCTCATTTGTTTGCCTCCCTG 3 '
AOX3MI1	5 ' TGCTCTAGATCTTAACATGAAGAATGTTTTAG 3 '
AOX3MI2	5 ' TCGGATCCGCTTAAGTGGAAGCTTCCAAAC 3 '

FIGURE SHOWING A PRODUCTION SCHEME OF EMBRYO LESS MAIZE GRAINS:
LINES A AND B ARE SOWN IN ALTERNATIVE ROWS (FOR EXAMPLE ONE MALE
AND FOUR FEMALES)



LEGEND
(REFER TO
DESCRIPTION
FOR DETAILS)



MALE PARENT A



FEMALE PARENT B

FIG. 5

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Gene Shears Pty. Limited
 - (B) STREET: Suite 1, Building 5, 105 Delhi Road
 - (C) CITY: North Ryde
 - (D) STATE: North Ryde
 - (E) COUNTRY: Australia
 - (F) POSTAL CODE (ZIP): NSW 2113
-
- (A) NAME: PAUL, Wyatt
 - (B) STREET: c/o Nickerson Biocem Ltd, Cambridge Science Park, Milton Rd
 - (C) CITY: Cambridge
 - (D) STATE: Cambridge
 - (E) COUNTRY: UK
 - (F) POSTAL CODE (ZIP): CB4 5GZ
-
- (A) NAME: PEREZ, Pascaul
 - (B) STREET: c/o Biogemma, Campus Universitaire des Cezeaux
 - (C) CITY: 24 Avenue des Landais
 - (D) STATE: Aubiere
 - (E) COUNTRY: France
 - (F) POSTAL CODE (ZIP): 63170
-
- (A) NAME: HUTTNER, Eric
 - (B) STREET: c/o Groupe Limagrain Pacific Pty Ltd, GPO Box 475
 - (C) CITY: Canberra
 - (D) STATE: Canberra, ACT
 - (E) COUNTRY: Australia
 - (F) POSTAL CODE (ZIP): 2601
-
- (A) NAME: BETZNER, Andreas Stefan
 - (B) STREET: Groupe Limagrain Pacific Pty Ltd, GPO Box 475
 - (C) CITY: Canberra
 - (D) STATE: Canberra, ACT
 - (E) COUNTRY: Australia
 - (F) POSTAL CODE (ZIP): 2601

(ii) TITLE OF INVENTION: Protein Complementation

(iii) NUMBER OF SEQUENCES: 68

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: WO PCT/GB98/00542

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 344 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION:9..344
- (D) OTHER INFORMATION:/product= "Barnase"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

TCTAGACC ATG GCA CAG GTT ATC AAC ACG TTT GAC GGG GTT GCG GAT TAT	50
Met Ala Gln Val Ile Asn Thr Phe Asp Gly Val Ala Asp Tyr	
1 5 10	
CTT CAG ACA TAT CAT AAG CTA CCT GAT AAT TAC ATT ACA AAA TCA GAA	98
Leu Gln Thr Tyr His Lys Leu Pro Asp Asn Tyr Ile Thr Lys Ser Glu	
15 20 25 30	
GCA CAA GCC CTC GGC TGG GTG GCA TCA AAA GGG AAC CTT GCA GAC GTC	146
Ala Gln Ala Leu Gly Trp Val Ala Ser Lys Gly Asn Leu Ala Asp Val	
35 40 45	
GCT CCG GGG AAA AGC ATC GGC GGA GAC ATC TTC TCA AAC AGG GAA GGC	194
Ala Pro Gly Lys Ser Ile Gly Gly Asp Ile Phe Ser Asn Arg Glu Gly	
50 55 60	
AAA CTC CCG GGC AAA AGC GGA CGA ACA TGG CGT GAA GCG GAT ATT AAC	242
Lys Leu Pro Gly Lys Ser Gly Arg Thr Trp Arg Glu Ala Asp Ile Asn	
65 70 75	
TAT ACA TCA GGC TTC AGA AAT TCA GAC CGG ATT CTT TAC TCA AGC GAC	290
Tyr Thr Ser Gly Phe Arg Asn Ser Asp Arg Ile Leu Tyr Ser Ser Asp	
80 85 90	
TGG CTG ATT TAC AAA ACA ACG GAC CAT TAT CAG ACC TTT ACA AAA ATC	338
Trp Leu Ile Tyr Lys Thr Thr Asp His Tyr Gln Thr Phe Thr Lys Ile	
95 100 105 110	
AGA TAA	344
Arg	

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 112 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Ala Gln Val Ile Asn Thr Phe Asp Gly Val Ala Asp Tyr Leu Gln
 1 5 10 15
 Thr Tyr His Lys Leu Pro Asp Asn Tyr Ile Thr Lys Ser Glu Ala Gln
 20 25 30
 Ala Leu Gly Trp Val Ala Ser Lys Gly Asn Leu Ala Asp Val Ala Pro
 35 40 45
 Gly Lys Ser Ile Gly Gly Asp Ile Phe Ser Asn Arg Glu Gly Lys Leu
 50 55 60
 Pro Gly Lys Ser Gly Arg Thr Trp Arg Glu Ala Asp Ile Asn Tyr Thr
 65 70 75 80
 Ser Gly Phe Arg Asn Ser Asp Arg Ile Leu Tyr Ser Ser Asp Trp Leu
 85 90 95
 Ile Tyr Lys Thr Thr Asp His Tyr Gln Thr Phe Thr Lys Ile Arg
 100 105 110

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..18
- (D) OTHER INFORMATION:/note= "Figure 1A: B1 primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CATGGTCTAG AGTACTTG

18

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..16
- (D) OTHER INFORMATION:/note= "Figure 1A: B4 primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

CCAGCCGAGG GCTTGT

16

(2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 16 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..16
- (D) OTHER INFORMATION:/note= "Figure 1A: B2 primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GCATCAAAAG GGAACC

16

(2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 228 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..228
- (D) OTHER INFORMATION:/note= "Figure 1B: Intergenic Sequence"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

CGAAAAAAC GGCTTCCTGC GGAGGCCGTT TTTTTCAGCT TTACATAAAG TGTGTAATAA	60
ATTTTCTTC AAACCTCTGAT CGGTCAATTT CACTTCCGG ATCCGGTCCA ATCTGCAGCC	120
GTCCGAGACA GGAGGACATC GTCCAGCTGA AACCGGGGCA GAATCCGGCC ATTTCTGAAG	180
AGAAAAATGG TAAACTGATA GAATAAAATC ATAAGAAAGG AGCCGCAC	228

(2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 323 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION:1..273

(D) OTHER INFORMATION:/product= "Barstar"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

ATG AAA AAA GCA GTC ATT AAC GGG GAA CAA ATC AGA AGT ATC AGC GAC	48
Met Lys Lys Ala Val Ile Asn Gly Glu Gln Ile Arg Ser Ile Ser Asp	
115 120 125	
CTC CAC CAG ACA TTG AAA AAG GAG CTT GCC CTT CCG GAA TAC TAC GGT	96
Leu His Gln Thr Leu Lys Lys Glu Leu Ala Leu Pro Glu Tyr Tyr Gly	
130 135 140	
GAA AAC CTG GAC GCT TTA TGG GAT TGT CTG ACC GGA TGG GTG GAG TAC	144
Glu Asn Leu Asp Ala Leu Trp Asp Cys Leu Thr Gly Trp Val Glu Tyr	
145 150 155 160	
CCG CTC GTT TTG GAA TGG AGG CAG TTT GAA CAA AGC AAG CAG CTG ACT	192
Pro Leu Val Leu Glu Trp Arg Gln Phe Glu Gln Ser Lys Gln Leu Thr	
165 170 175	
GAA AAT GGC GCC GAG AGT GTG CTT CAG GTT TTC CGT GAA GCG AAA GCG	240
Glu Asn Gly Ala Glu Ser Val Leu Gln Val Phe Arg Glu Ala Lys Ala	
180 185 190	
GAA GGC TGC GAC ATC ACC ATC ATA CTT TCT TAA TACGATCAAT GGGAGATGAA	293
Glu Gly Cys Asp Ile Thr Ile Ile Leu Ser	
195 200	
CAATATAGAT CCCCCGGGCT GCAGGAATTC	323

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 91 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Lys Lys Ala Val Ile Asn Gly Glu Gln Ile Arg Ser Ile Ser Asp	
1 5 10 15	
Leu His Gln Thr Leu Lys Lys Glu Leu Ala Leu Pro Glu Tyr Tyr Gly	
20 25 30	
Glu Asn Leu Asp Ala Leu Trp Asp Cys Leu Thr Gly Trp Val Glu Tyr	
35 40 45	
Pro Leu Val Leu Glu Trp Arg Gln Phe Glu Gln Ser Lys Gln Leu Thr	
50 55 60	

Glu Asn Gly Ala Glu Ser Val Leu Gln Val Phe Arg Glu Ala Lys Ala
 65 70 75 80

Glu Gly Cys Asp Ile Thr Ile Ile Leu Ser
 85 90

(2) INFORMATION FOR SEQ ID NO: 9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..21
- (D) OTHER INFORMATION:/note= "Figure 1C: B3 primer"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

TAATACGATC AATGGGAGAT G

21

(2) INFORMATION FOR SEQ ID NO: 10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 194 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION:9..194
- (D) OTHER INFORMATION:/note= "Figure 1D"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

TCTAGACC ATG GCA CAG GTT ATC AAC ACG TTT GAC GGG GTT GCG GAT TAT 50
 Met Ala Gln Val Ile Asn Thr Phe Asp Gly Val Ala Asp Tyr
 95 100 105

CTT CAG ACA TAT CAT AAG CTA CCT GAT AAT TAC ATT ACA AAA TCA GAA 98
 Leu Gln Thr Tyr His Lys Leu Pro Asp Asn Tyr Ile Thr Lys Ser Glu
 110 115 120

GCA CAA GCC CTC GGC TGG ATG GGC GGT GGC GGT TCC GGT GGC GGT GGC 146
 Ala Gln Ala Leu Gly Trp Met Gly Gly Gly Gly Ser Gly Gly Gly Gly
 125 130 135

AGC GGC GGC GGT GGT AGC GGG ATC CCC GGG TAC GGT CAG TCC CTT ATG 194
 Ser Gly Gly Gly Gly Ser Gly Ile Pro Gly Tyr Gly Gln Ser Leu Met
 140 145 150

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 62 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Met Ala Gln Val Ile Asn Thr Phe Asp Gly Val Ala Asp Tyr Leu Gln
 1 5 10 15
 Thr Tyr His Lys Leu Pro Asp Asn Tyr Ile Thr Lys Ser Glu Ala Gln
 20 25 30
 Ala Leu Gly Trp Met Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
 35 40 45
 Gly Gly Gly Ser Gly Ile Pro Gly Tyr Gly Gln Ser Leu Met
 50 55 60

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 526 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..526
- (D) OTHER INFORMATION:/note= "Figure 1E"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

TCTAGACCAT GCAGATCTTC GTGAAAACCT TGACCGGCAA GACCATCACT CTCGAGGTCG 60
 AGAGCAGCGA CACCATCGAC AATGTCAAGG CCAAGATCCA AGACAAAGAA GGTATCATTC 120
 TTCCTCACTC AATCTGGATT CTTCTCTTTA GCTTTTTGAA ATTCAGATCT CTTATCATTT 180
 ACTTGTTTCT CCTTTAAGGA ATCCCTCCGG ATCAGCAGAG ATTGATCTTC GCCGGAAGC 240
 AGCTCGAAGA TGGCCGTACT TTGGCTGACT ACAACATCCA GAAAGGTACG AAATCATCCG 300
 AATCCTTCTG TTGATCATTT CGATGATCTG ATTGTATAAA CTCTAATGGA TTGTTATCAT 360
 TTGTAAACAG AATCTAGACT TCATCTTGTTG TTGAGGCTTA GAGGTGGAGC ACAGGTTATC 420
 AACACGTTTG ACGGGGTTGC GGATTATCTT CAGACATATC ATAAGCTACC TGATAATTAC 480

(2) INFORMATION FOR SEQ ID NO: 13:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 631 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..631
- (D) OTHER INFORMATION:/note= "Figure 1F"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

TCTAGACCAT GCAGATCTTC GTGAAACCT TGACCGGCAA GACCATCACT CTCGAGGTCTG	60
AGAGCAGCGA CCATCGACAA TGTCAAGGCC AAGATCCAAG ACAAAGAAGG TATCATTCTT	120
CCTCACTCAA TCTGGATTCT TCTCTTTAGC TTTTGAAAT TCAGATCTCT TATCATTTAC	180
TTGTTTCTCC TTTAAGGAAT CCCTCCGGAT CAGCAGAGAT TGATCTTCGC CGGAAAGCAG	240
CTCGAAGATG GCCGTACTTT GGCTGACTAC AACATCCAGA AAGGTACGAA ATCATCCGAA	300
TCCTTCTGTT GATCATTTTCG ATGATCTGAT TGTATAAACT CTAATGGATT GTTATCATTT	360
GTAAACAGAA TCTACACTTC ATCTTGTGTT GAGGCTTAGA GGTGGAGCAT CAAAAGGGAA	420
CCTTGCAGAC GTCGCTCCGG GGAAAAGCAT CGGCGGAGAC ATCTTCTCAA ACAGGGAAGG	480
CAAACTCCCG GGCAAAAGCG GACGAACATG GCGTGAAGCG GATATTAACT ATACATCAGG	540
CTTCAGAAAT TCAGACCGGA TTCTTTACTC AAGCGACTGG CTGATTTACA AAACAACGGA	600
CCATTATCAG ACCTTTACAA AAATCAGATA A	631

(2) INFORMATION FOR SEQ ID NO: 14:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..20
- (D) OTHER INFORMATION:/note= "Figure 1G: B5"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

CACAAGTACT CTAGACCATG

20

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..19
- (D) OTHER INFORMATION:/note= "Figure 1G: B6"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

CATCCAGCCG AGGGCTTGT

19

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..16
- (D) OTHER INFORMATION:/note= "Figure 1G: B7"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

GGCGGTGGCG GTTCCG

16

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..23
- (D) OTHER INFORMATION:/note= "Figure 1G: B8"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

CCACTAGTTC TAGAGTACTT GTG

23

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..18
- (D) OTHER INFORMATION:/note= "Figure 1G: B9"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

GCACAGGTTA TCAACACG

18

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..31
- (D) OTHER INFORMATION:/note= "Figure 1G: B10"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

GCGGATCCTC TACATCCAGC CGAGGGCTTG T

31

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature

(B) LOCATION:1..16
(D) OTHER INFORMATION:/note= "Figure 1G: B11"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

GCATCAAAAG GGAACC

16

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:1..17
(D) OTHER INFORMATION:/note= "Figure 1G: B12"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

GGTCTAGAGT ACTTGTG

17

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(B) LOCATION:1..30
(D) OTHER INFORMATION:/note= "Figure 1G: Ubq16F"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

GCTCTAGACC ATGCAGATCT TCGTGAAAAC

30

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..25
- (D) OTHER INFORMATION:/note= "Figure 1G: UbqlR"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

CTGGATCCAC CTCTAAGCCT CAACA

25

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..24
- (D) OTHER INFORMATION:/note= "Figure 1G: Ubqla"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

TATGGATCCC CCGGGCTGCA GGAA

24

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..21
- (D) OTHER INFORMATION:/note= "Figure 1G: Ubqlb"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

TCCACCTCTA AGCCTCAACA C

21

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..23
- (D) OTHER INFORMATION:/note= "Fig 3A: lane 1, Primer RNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

GCGGATCCAT GAAGGAGACC GCC

23

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 56 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..56
- (D) OTHER INFORMATION:/note= "Fig 3A; lane 2, RNI"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

GCGGATCCAT GAAGGAGACC GCCGCCGCCA AGTTCGAGCG CCAGCACATG GACAGC

56

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..22
- (D) OTHER INFORMATION:/note= "Fig 3A: lane 3, RN1"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

CATAGATCTT TAGCTGTCCA TG

22

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION:1..28

(D) OTHER INFORMATION:/note= "Fig 3A: lane 4, Primer
RN-d"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

CCAGATCTAT GAGCTCCTCC AACTACTG

28

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 63 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION:1..63

(D) OTHER INFORMATION:/note= "Fig 3A: lanes 2/5, RNII"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

TAAAGATCTA TGAGCACCTC CGCCGCCAGC TCCTCCAACCT ACTGCAACCA GATGATGAAG

60

TCT

63

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION:1..21

(D) OTHER INFORMATION:/note= "Fig 3A: lane 6, RN2"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

TCAGGTTTCCT AGACTTCATC A

21

(2) INFORMATION FOR SEQ ID NO: 32:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 59 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION:1..59
 (D) OTHER INFORMATION:/note= "Fig 3A, lanes 5/7, RNIII"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

AGGAACCTGA CCAAGGACAG GTGCAAGCCA GTCAACACCT TCGTCCACGA GAGCCTGGC

59

(2) INFORMATION FOR SEQ ID NO: 33:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION:1..19
 (D) OTHER INFORMATION:/note= "Fig 3A: lane 8, RN3"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

CTGGACATCG GCCAGGCTC

19

(2) INFORMATION FOR SEQ ID NO: 34:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 48 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:
 (A) NAME/KEY: misc_feature
 (B) LOCATION:1..48
 (D) OTHER INFORMATION:/note= "Fig 3A, lanes 7/9, RN IV"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

CGATGTCCAG GCCGTCTGCA GCCAGAAGAA CGTGGCCTGC AAGAACGG

48

(2) INFORMATION FOR SEQ ID NO: 35:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
 (B) LOCATION:1..21
 (D) OTHER INFORMATION:/note= "Fig 3A: lane 10, RN 4"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

AGTTGGTCTG ACCGTTCTTG C

21

(2) INFORMATION FOR SEQ ID NO: 36:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 60 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
 (B) LOCATION:1..60
 (D) OTHER INFORMATION:/note= "Fig 3A: lanes 9/11, RN V"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

TCAGACCAAC TGCTACCACT CCTACAGCAC CATGTCCATC ACCGACTGCC GCGAGACCGG

60

(2) INFORMATION FOR SEQ ID NO: 37:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 19 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
 (B) LOCATION:1..19
 (D) OTHER INFORMATION:/note= "Fig 3A: lane 12, RN5"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

CTTGCTGGAG CCGGTCTCG

19

(2) INFORMATION FOR SEQ ID NO: 38:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 55 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..55
- (D) OTHER INFORMATION:/note= "Fig 3A: lanes 11/13, RN VI"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

CTCCAGCAAG TACCCTAACT GCGCCTACAA GACCACCCAG GCCAACAAGC ACATC

55

(2) INFORMATION FOR SEQ ID NO: 39:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..21
- (D) OTHER INFORMATION:/note= "Fig 3A: lane 14, RN 6"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

CAGGCAACAA TGATGTGCTT G

21

(2) INFORMATION FOR SEQ ID NO: 40:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..24
- (D) OTHER INFORMATION:/note= "Fig 3A: lane 15, Primer RN-b"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

CGGGATCCTT TAGACGGAGG CGTC

24

(2) INFORMATION FOR SEQ ID NO: 41:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 66 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..66
- (D) OTHER INFORMATION:/note= "Fig 3A: lanes 13/16, RN VII"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

ATTGTTGCCT GCGAGGGTAA CCCTTACGTG CCTGTCCACT TCGACGCCTC CGTCTAAAGG

60

ATCCCG

66

(2) INFORMATION FOR SEQ ID NO: 42:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 23 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..23
- (D) OTHER INFORMATION:/note= "Fig 3B: lane 1, PCR Primer RNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

GCGGATCCAT GAAGGAGACC GCC

23

(2) INFORMATION FOR SEQ ID NO: 43:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 56 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..56
- (D) OTHER INFORMATION:/note= "Fig 3B, lane 2, RN I"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

GCGGATCCAT GAAGGAGACC GCCGCCGCCA AGTTCGAGCG CCAGCACATG GACAGC

56

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..18
- (D) OTHER INFORMATION:/note= "Fig 3B, lane 3, RN 7"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

CCACCGCCGC TGTCCATG

18

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 57 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..57
- (D) OTHER INFORMATION:/note= "Fig 3B: lanes 2/4, RN VIII"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

GGCGGTGGCG GTTCCGGTGG CGGTGGCAGC GCGCGCGGTG GTAGCAAGAT CTTCGGG

57

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..18
- (D) OTHER INFORMATION:/note= "Fig 3B: lane 5, RN c"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

CCCGAAGATC TTGCTACC

18

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 45 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..45
- (D) OTHER INFORMATION:/note= "Fig 4, lane 1"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

AAAGAGACAG CAGCCGCAAA GTTTGAGCGT CAGCATATGG ATAGT

45

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION:1..32
- (D) OTHER INFORMATION:/note= "Fig 4A: lane 2"

(ix) FEATURE:

- (A) NAME/KEY: Modified-site
- (B) LOCATION:17
- (D) OTHER INFORMATION:/note= "'Xaa" = corresponds to an ochre stop codon (UAA)"

[illegible]

Met Lys Glu Thr Ala Ala Ala Lys Phe Glu Arg Gln His Met Asp Ser
1 5 10 15

Xaa Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
20 25 30

(2) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 63 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
(B) LOCATION:1..63
(D) OTHER INFORMATION:/note= "Fig 4A: lane 3"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

GGATCCATGA AGGAGACCGC CGCCGCCAAG TTCGAGCGCC AGCACATGGA CAGCTAAAGA 60

TCT 63

(2) INFORMATION FOR SEQ ID NO: 50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 106 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
(B) LOCATION:1..106
(D) OTHER INFORMATION:/note= "Fig 4A: lane 4"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

GGATCCATGA AGGAGACCGC CGCCGCCAAG TTCGAGCGCC AGCACATGGA CAGCGGCGGT 60

GGCGGTTCCG GTGGCGGTGG CAGCGGCGGC GGTGGTAGCA AGATCT 106

(2) INFORMATION FOR SEQ ID NO: 51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 330 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: misc_feature

(B) LOCATION:1..330

(D) OTHER INFORMATION:/note= "Fig 4B: lane 1"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

AGCACCAGTG CTGCCAGTTC TTCCAAC TAC TGTAACCAGA TGATGAAGTC TAGAAACTTG	60
ACCAAGGACA GATGTAAGCC AGTTAACACA TTTGTCCACG AGAGTTTGGC TGATGTCCAA	120
GCCGTCTGCA GTCAGAAAAA CGTTGCATGC AAGAACGGTC AAACGAACTG TTACCAGAGT	180
TACAGCACCA TGTCCATCAC TGACTGTCGT GAGACAGGCT CGAGCAAGTA TCCTAATTGT	240
GCTTACAAGA CCACACAGGC GAACAAACAC ATCATTGTTG CTTGTGAAGG TAACCCTTAC	300
GTTCTGTCC ACTTTGACGC CAGTGTTTAA	330

(2) INFORMATION FOR SEQ ID NO: 52:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 132 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

(A) NAME/KEY: Peptide

(B) LOCATION:1..132

(D) OTHER INFORMATION:/note= "Fig 4B: lane 2"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

Met Ser Thr Ser Ala Ala Ser Ser Ser Asn Tyr Cys Asn Gln Met Met	
1	5 10 15
Lys Ser Arg Asn Leu Thr Lys Asp Arg Cys Lys Pro Val Asn Thr Phe	
	20 25 30
Val His Glu Ser Leu Ala Asp Val Gln Ala Val Cys Ser Gln Lys Asn	
	35 40 45
Val Ala Cys Lys Asn Gly Gln Thr Asn Cys Tyr Gln Ser Tyr Ser Thr	
	50 55 60
Met Ser Ile Thr Asp Cys Arg Glu Thr Gly Ser Ser Lys Tyr Pro Asn	
65	70 75 80
Cys Ala Tyr Lys Thr Thr Gln Ala Asn Thr Asp Cys Arg Glu Thr Gly	
	85 90 95

Ser Ser Lys Tyr Pro Asn Cys Ala Tyr Lys Thr Thr Gln Ala Asn Lys
100 105 110
His Ile Ile Val Ala Cys Glu Gly Asn Pro Tyr Val Pro Val His Phe
115 120 125
Asp Ala Ser Val
130

(2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 346 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..330
- (D) OTHER INFORMATION:/note= "Fig 4B, lane 3"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

AGATCTATGA GCACCTCCGC CGCCAGCTCC TCCAACACT GCAACCAGAT GATGAAGTCT	60
AGGAACCTGA CCAAGGACAG GTGCAAGCCA GTCAACACCT TCGTCCACGA GAGCCTGGCC	120
GATGTCCAGG CCGTCTGCAG CCAGAAGAAC GTGGCCTGCA AGAACGGTCA GACCAACTGC	180
TACCAGTCCT ACAGCACCAT GTCCATCACC GACTGCCGCG AGACCGGCTC CAGCAAGTAC	240
CCTAACTGCG CCTACAAGAC CACCCAGGCC AACAAGCACA TCATTGTTGC CTGCGAGGGT	300
AACCCCTTACG TGCCTGTCCA CTTGACGCC TCCGTCTAAA GGATCC	346

(2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 331 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..331
- (D) OTHER INFORMATION:/note= "Fig 4B, lane 4"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

AGATCTATGA GTCCTCCAA CTAAGTCAAC CAGATGATGA AGTCTAGGAA CCTGACCAAG	60
--	----

(2) INFORMATION FOR SEQ ID NO: 57:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 270 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..270
- (D) OTHER INFORMATION:/note= "Fig 4c iii"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

ATGAAGAATG TTTTAGTAAG GTCAGCTGCG CGAGCTCTGC TTGGCGGCGG TGGGCGGAGC	60
TACTACCGCC AGCTCTCAAC GCGGCGGATC GTGGAACAGA GACACCAGCA CGGTGGCGGC	120
GCGTTTGAA GCTTCCACTT AAGAAGGATG AAGGAGACCG CCGCCGCCAA GTTCGAGCGC	180
CAGCACATGG ACAGCGGCGG TGGCGGTTCC GGTGGCGGTG GCAGCGGCGG CGGTGGTAGC	240
GGGATCCCCG GGTACGGTCA GTCCCTTATG	270

(2) INFORMATION FOR SEQ ID NO: 58:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 465 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION:1..465
- (D) OTHER INFORMATION:/note= "Fig 4C iv"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

ATGAAGAATG TTTTAGTAAG GTCAGCTGCG CGAGCTCTGC TTGGCGGCGG TGGGCGGAGC	60
TACTACCGCC AGCTCTCAAC GCGGCGGATC GTGGAACAGA GACACCAGCA CGGTGGCGGC	120
GCGTTTGAA GCTTCCACTT AAGAAGGATG AGCTCCTCCA ACTACTGCAA CCAGATGATG	180
AAGTCTAGGA ACCTGACCAA GGACAGGTGC AAGCCAGTCA ACACCTCCGT CCACGAGAGC	240
CTGGCCGATG TCCAGGCCGT CTGCAGCCAG AAGAACGTGG CCTGCAAGAA CGGTCAGACC	300
AACTGCTACC AGTCCTACAG CACCATGTCC ATCACCGACT GCCGCGAGAC CGGCTCCAGC	360

AAGTACCCTA ACTGCGCCTA CAAGACCACA CAGGCCAACA AGCACATCAT TGTTCCTGC	420
GAGGGTAACC CTTACGTGCC TGTCCACTTC GACGCCTCCG TCTAA	465

(2) INFORMATION FOR SEQ ID NO: 59:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 715 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 1..715
- (D) OTHER INFORMATION: /note= "Fig 4C v"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

ATGCAGATCT TCGTGAAAAC CTTGACCGGC AAGACCATCA CTCTCGAGGT CGAGAGCAGC	60
GACACCATCG ACAATGTCAA GGCCAAGATC CAAGACAAAG AAGGTATCAT TCTTCCTCAC	120
TCAATCTGGA TTCTTCTCTT TAGCTTTTGT AAATTCAGAT CTCTTATCAT TTAATTGTTT	180
CTCCTTTAAG GAATCCCTCC GGATCAGCAG AGATTGATCT TCGCCGGAAA GCAGCTCGAA	240
GATGGCCGTA CTTTGGCTGA CTACAACATC CAGAAAGGTA CGAAATCATC CGAATCCTTC	300
TGTTGATCAT TTCGATGATC TGATTGTATA AACTCTAATG GATTGTTATC ATTTGTAAAC	360
AGAATCTACA CTTTCATCTTG TGTTGAGGCT TAGAGGTGGA TCCAGCTCCA ACTACTGCAA	420
CCAGATGATG AAGTCTAGGA ACCTGACCAA GGACAGGTGC AAGCCAGTCA ACACCTCCGT	480
CCACGAGAGC CTGGCCGATG TCCAGGCCGT CTGCAGCCAG AAGAACGTGG CCTGCAAGAA	540
CGGTCAGACC AACTGCTACC AGTCCTACAG CACCATGTCC ATCACC GACT GCCGCGAGAC	600
CGGCTCCAGC AAGTACCCTA ACTGCGCCTA CAAGACCACA CAGGCCAACA AGCACATCAT	660
TGTTCCTGC GAGGGTAACC CTTACGTGCC TGTCCACTTC GACGCCTCCG TCTAA	715

(2) INFORMATION FOR SEQ ID NO: 60:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

GGTGGATCCA GCTCCAACTA CTGCAAC

27

(2) INFORMATION FOR SEQ ID NO: 61:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

CGGGATCCTT AGACGGAGGC GTCG

24

(2) INFORMATION FOR SEQ ID NO: 62:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 31 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

GTCCTTAAGA AGGATGAGCT CCTCCAACTA C

31

(2) INFORMATION FOR SEQ ID NO: 63:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

CGGGATCCTT AGACGGAGGC GTCG

24

(2) INFORMATION FOR SEQ ID NO: 64:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

GTCCTTAAGA AGGATGAAGG AGACCGCCG

29

(2) INFORMATION FOR SEQ ID NO: 65:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

TCGGGATCCT TAGCTGTCCA TGTGCTG

27

(2) INFORMATION FOR SEQ ID NO: 66:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 27 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

TCGGGATCCT CATTGTTTGC CTCCTG

27

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

TGCTCTAGAT CTTAACATGA AGAATGTTTT AG

32

(2) INFORMATION FOR SEQ ID NO: 68:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

TCGGATCCGC TTAAGTGGAA GCTTCCAAAC

DECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PROTEIN COMPLEMENTATION IN TRANSGENIC PLANTS

*the specification of which:
(check one)*

 X is attached hereto.

 was filed on _____ as

Application Serial No _____

and was amended _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 (a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International Application which designated at least one country other than the United States, listed below. I have also identified below any foreign application for patent or inventor's certificate, or PCT International Application having a filing date before that of the earliest application from which priority is claimed:

Prior Foreign Application(s)

Priority Claimed

<u>Number</u>	<u>Country</u>	<u>Filing Date</u>	<u>Yes</u>	<u>No</u>
PCT/GB98/00542	PCT	20 February 1998	X	_____
9703681.8	United Kingdom	21 February 1997	X	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

<u>Provisional Application No.</u>	<u>Filing Date</u>	<u>Status</u>
N/A		

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States Application(s), or Section 365(c) of any PCT International Application(s) designating the United States listed below. Insofar as this application discloses and claims subject matter in addition to that disclosed in any such prior Application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56, which became available between the filing date(s) of such prior Application(s) and the national or PCT international filing date of this application:

<u>Application Serial No.</u>	<u>Filing Date</u>	<u>Status</u>
PCT/GB98/00542	20 February 1998	Pending

And I hereby appoint

John P. White (Reg. No. 28,678); Christopher C. Dunham (Reg. No. 22,031); Norman H. Zivin (Reg. No. 25,385); Jay H. Maioli (Reg. No. 27,213); William E. Pelton (Reg. No. 25,702); Robert D. Katz (Reg. No. 30,141); Peter J. Phillips (Reg. No. 29,691); Wendy E. Miller (Reg. No. 35,615); Richard S. Milner (Reg. No. 33,970); Albert Wai-Kit Chan (Reg. No. 36,479); Robert T. Maldonado (Reg. 38,232); Paul Teng (40,837); George M. MacDonald (Reg. No. 39,284); Richard F. Jaworski (Reg. No. 33,515); Elizabeth M. Wieckowski (Reg. No. 42,226); Pedro C. Fernandez (Reg. No. 41,741); and Gary J. Gershtik (Reg. No. 39,992).

and each of them, all c/o Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, New York 10036, my attorneys, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, to transact all business in the Patent and Trademark Office connected therewith and to file any International Applications which are based thereon under the provisions of the Patent Cooperation Treaty.

Please address all communications, and direct all telephone calls, regarding this application to.

John P. White

Reg. No. 28,678

Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. (212) 278-0400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or
first joint inventor Wyatt Paul

Inventor's signature

Citizenship Great Britain

Date of signature

Residence

Post Office Address C/O Nickerson Biocem Limited, Cambridge Science Park,
Milton Road, Cambridge CB4 4GZ UK

Full name of joint
inventor (if any) Pascual Perez

Inventor's signature

Citizenship France

Date of signature

Residence

Post Office Address C/O Biogemma, Campus Universitaire des Cezeaux
24 Avenue des Landais 63170 Aubiere France

Full name of joint
inventor (if any) Eric Huttner

Inventor's signature

Citizenship France

Date of signature

Residence

Post Office Address C/O Groupe Limagrain Pacific Pty. Limited, Research School
of Biological Sciences, The Australian National University
GPO Box 475, Canberra, ACT, 2601 Australia

Full name of joint

inventor (if any) Andreas Stefan Betzner

Inventor's signature _____

Citizenship Germany

Date of signature _____

Residence _____

Post Office Address Groupe Limagrain Pacific Pty. Limited, Research School of

Biological Sciences, The Australian National University

GPO Box 475, Canberra, ACT, 2601 Australia

Full name of joint

inventor (if any) _____

Inventor's signature _____

Citizenship _____

Date of signature _____

Residence _____

Post Office Address _____

Full name of joint

inventor (if any) _____

Inventor's signature _____

Citizenship _____

Date of signature _____

Residence _____

Post Office Address _____